[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2835
6. Inukai T, Zhang X, Kameyama T, Suzuki Y, Yoshikawa K, Kuroda I, Nemoto A, Akahane K, Sato H, Goi K, Nakamoto K, Hamada J, Tada M, Moriuchi T, Sugita K: A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines. Am J Hematol; 2010 Jul;85(7):535-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
  • [MeSH-major] Mutation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. Oncogene Proteins, Fusion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575032.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimarães H, Areias JC, Correia-Pinto J: N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology; 2008;94(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants.
  • Plasmatic N-terminal-pro-B type natriuretic peptide (NT-proBNP) might be useful in diagnosis and management of PH in newborns, although its interest in CDH infants remains to be defined.
  • [MeSH-major] Heart / physiopathology. Hernia, Diaphragmatic / physiopathology. Hernias, Diaphragmatic, Congenital. Hypertension, Pulmonary / blood. Hypertension, Pulmonary / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18160811.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


8. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM: Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol; 2006 Aug 15;98(4):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
  • The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC.
  • Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing.
  • The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001).
  • NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012).
  • There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003).
  • On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max.
  • A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%.
  • In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893708.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


9. Thummes K, Schäfer J, Kämpfer P, Jäckel U: Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments. Syst Appl Microbiol; 2007 Dec;30(8):634-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments.
  • Since compost is widely used as soil amendment and the fact that during the processing of compost material high amounts of microorganisms are released into the air, we investigated whether compost may act as a carrier for thermophilic methanogens to temperate soils.
  • All eight investigated compost materials showed a clear methane production potential between 0.01 and 0.98 micromol CH(4) g dw(-1)h(-1) at 50 degrees C.
  • Single strand conformation polymorphism (SSCP) and cloning analysis indicated the presence of Methanosarcina thermophila, Methanoculleus thermophilus, and Methanobacterium formicicum.
  • Bioaerosols collected during the turning of a compost pile showed both a highly similar SSCP profile compared to the corresponding compost material and clear methane production during anoxic incubation in selective medium at 50 degrees C.
  • Both observations indicated a considerable release of thermophilic methanogens into the air.
  • To analyse the persistence of compost-borne thermophilic methanogens in temperate oxic soils, we therefore studied their potential activity in compost and compost/soil mixtures, which was brought to a meadow soil, as well as in an agricultural soil fertilised with compost.
  • After 24h anoxic incubation at 50 degrees C, all samples containing compost showed a clear methanogenic activity, even 1 year after application.
  • In combination with the in vitro observed resilience of the compost-borne methanogens against desiccation and UV radiation we assume that compost material acts as an effective carrier for the distribution of thermophilic methanogens by fertilisation and wind.
  • [MeSH-major] Methane / biosynthesis. Methanobacterium / isolation & purification. Methanomicrobiaceae / isolation & purification. Methanosarcina / isolation & purification. Soil Microbiology
  • [MeSH-minor] DNA, Bacterial / genetics. Desiccation. Hot Temperature. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Ultraviolet Rays

  • Hazardous Substances Data Bank. METHANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988815.001).
  • [ISSN] 0723-2020
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AM747292/ AM747293/ AM747294/ AM747295/ AM747296/ AM747297/ AM747298/ AM747299/ AM747300/ AM747301
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; OP0UW79H66 / Methane
  •  go-up   go-down


10. Victor S, Marson AG, Appleton RE, Beirne M, Weindling AM: Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants. Pediatr Res; 2006 Feb;59(2):314-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants.
  • There is uncertainty about the level of systemic blood pressure required to maintain adequate cerebral oxygen delivery and organ integrity.
  • This prospective, observational study on 35 very low birth weight infants aimed to determine the mean blood pressure (MBP) below which cerebral electrical activity, peripheral blood flow (PBF), and cerebral fractional oxygen extraction (CFOE) are abnormal.
  • Digital EEG, recorded every day on the first 4 d after birth, were analyzed a) by automatic spectral analysis, b) by manual measurement of interburst interval, and c) qualitatively.
  • CFOE and PBF measurements were performed using near-infrared spectroscopy and venous occlusion.
  • MBP was measured using arterial catheters.
  • The median (range) of MBP recorded was 32 mm Hg (16-46).
  • The EEG became abnormal at MBP levels below 23 mm Hg: a) the relative power of the delta (0.5-3.5 Hz) frequency band was decreased, b) interburst intervals were prolonged, and c) all four qualitatively abnormal EEG (low amplitude and prolonged interburst intervals) from four different patients were recorded below this MBP level.
  • The only abnormally high CFOE was measured at MBP of 20 mm Hg.
  • PBF decreased at MBP levels between 23 and 33 mm Hg.
  • None of the infants in this study developed cystic periventricular leukomalacia.
  • One infant (MBP, 22 mm Hg) developed ventricular dilatation after intraventricular hemorrhage.
  • The EEG and CFOE remained normal at MBP levels above 23 mm Hg.
  • It would appear that cerebral perfusion is probably maintained at MBP levels above 23 mm Hg.
  • [MeSH-major] Blood Pressure. Brain / physiology. Cerebrovascular Circulation. Infant, Very Low Birth Weight / physiology. Oxygen / metabolism
  • [MeSH-minor] Electroencephalography. Fourier Analysis. Humans. Infant, Newborn

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439599.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


11. Hou Y, Hu Q, Liu AG, Zhang LQ, Liu SY: [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr;8(2):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
  • OBJECTIVE: Survivin, a unique member of the inhibitor of apoptosis protein (IAP) family, plays an important role in regulating both apoptosis and cell division.
  • METHODS: The expression of survivin protein was detected by immunohistochemical assay in bone marrow cells from 62 children with acute leukemia and 40 hospitalized children who did not have leukemia (Control group), and in a human acute T lymphocytic leukemia cell line (Molt-4 cells) treated in vitro with daunorubicin (DNR).
  • Cell apoptosis was detected using flow cytometry.
  • RESULTS: Survivin protein was expressed in 41.9% of the 62 children with acute leukemia but in only 5.0% of the Control group (chi(2)=16.66; P < 0.01).
  • The expression rate of survivin was 46.2% in cytoplasm and 53.9% in nucleus in the children with acute leukemia (chi(2)0.3077; P> 0.05).
  • DNR treatment also induced survivin transllocation from cytoplasm to nucleus and cell apoptosis in a time and dosage-dependent manner.
  • CONCLUSIONS: Survivin may play an important role in the development and prognosis of childhood acute leukemia.
  • The different expression pattern of survivin in the cytoplasm and the nucleus may be associated with therapeutic efficacy and prognosis in acute leukemia.
  • DNR may reduce the survivin expression in leukemic cells and induce cell apoptosis.
  • [MeSH-major] Bone Marrow Cells / chemistry. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613699.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


12. Sherborne AL, Houlston RS: What are genome-wide association studies telling us about B-cell tumor development? Oncotarget; 2010 Sep;1(5):367-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What are genome-wide association studies telling us about B-cell tumor development?
  • It has long been speculated that common genetic variation influences the development of B-cell malignancy, however until recently evidence for this assertion was lacking.
  • Recent GWAS of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) have identified novel disease genes for CLL and ALL and underscore the importance of polymorphic variation in B-cell development genes as determinants of leukemia risk.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Blood. 2010 Mar 4;115(9):1765-7 [20042726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):657-62 [9435248.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):230-42 [15738953.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1025-8 [15800670.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3565-75 [16177824.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):195-201 [16616066.001]
  • [Cites] Leukemia. 2002 Feb;16(2):297-8 [11840299.001]
  • [Cites] Cell Growth Differ. 2002 Mar;13(3):95-106 [11959810.001]
  • [Cites] J Virol. 2002 Nov;76(21):11133-8 [12368356.001]
  • [Cites] Annu Rev Immunol. 2004;22:55-79 [15032574.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):652-8 [16682969.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3451-61 [17170124.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Nat Genet. 2008 Nov;40(11):1307-12 [18794855.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4028-38 [18799728.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5568-74 [19549893.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):885-90 [19561604.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1001-5 [19684603.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1006-10 [19684604.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):238-45 [18503587.001]
  • [Cites] Nat Genet. 2010 Feb;42(2):132-6 [20062064.001]
  • [Cites] Cell. 1994 Oct 7;79(1):143-56 [7923373.001]
  • (PMID = 21307401.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3157732
  •  go-up   go-down


13. Szczepanek J, Pogorzala M, Konatkowska B, Juraszewska E, Badowska W, Olejnik I, Kuzmicz M, Stanczak E, Malinowska I, Stefaniak J, Sobol G, Szczepanski T, Czyzewski K, Wysocki M, Styczynski J: Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res; 2010 Jun;30(6):2119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
  • The objective of this study was the analysis of the ex vivo activity of bortezomib in paediatric acute lymphoblastic leukaemia (ALL), in comparison to paediatric acute myeloid leukaemia (AML).
  • A total of 159 patients entered the study, including 106 ALL (including 86 precursor-B-cell ALL, and 20 T-cell ALL) and 53 AML children.
  • With respect to immunophenotype, ex vivo drug resistance in T-cell ALL (T-ALL) was higher for most of the drugs.
  • No differences in drug resistance between T-ALL and common/pre-B-cell-ALL were found for daunorubicin, mitoxantrone and 6-thioguanine.
  • Bortezomib was the only compound which was more active in T-ALL than in common/pre-B-ALL paediatric samples.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651360.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


1
Advertisement
4. Coleman CB, Nealy MS, Tibbetts SA: Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J Virol; 2010 Dec;84(24):13045-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gammaherpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 [HHV-8]), Epstein-Barr virus (EBV), and murine gammaherpesvirus 68 (MHV68; also known as gammaherpesvirus 68 [γHV68] or murine herpesvirus 4 [MuHV-4]), establish lifelong latency in the resting memory B cell compartment.
  • However, little is known about how this reservoir of infected mature B cells is maintained for the life of the host.
  • In the context of a normal immune system, the mature B cell pool is naturally maintained by the renewable populations of developing B cells that arise from hematopoiesis.
  • Thus, recurrent infection of these developing B cell populations could allow the virus continual access to the B cell lineage and, subsequent to differentiation, the memory B cell compartment.
  • In work described here, we demonstrate the presence of viral genome in bone marrow pro-pre-B cells and immature B cells during early latency and immature B cells during long-term latency.
  • Because developing B cells normally exhibit a short life span and a high rate of turnover, these findings suggest a model in which gammaherpesviruses may gain access to the mature B cell compartment by recurrent seeding of developing B cells.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Feb;74(3):1101-13 [10627520.001]
  • [Cites] J Virol. 2010 Aug;84(15):7523-34 [20484501.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):6834-40 [11739500.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] J Virol. 2002 Jul;76(14):7125-32 [12072512.001]
  • [Cites] J Virol. 2003 Feb;77(4):2522-9 [12551990.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3828-34 [12646650.001]
  • [Cites] J Virol. 2003 Jul;77(13):7308-18 [12805429.001]
  • [Cites] J Virol. 2003 Jul;77(13):7696-701 [12805472.001]
  • [Cites] Cancer. 1979 Sep;44(3):993-1002 [225008.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4262-79 [7030473.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):290-3 [6321323.001]
  • [Cites] Transplantation. 1985 May;39(5):461-72 [2986325.001]
  • [Cites] Blood. 1985 May;65(5):1097-104 [2986741.001]
  • [Cites] Blood. 1988 May;71(5):1234-43 [2833957.001]
  • [Cites] Blood. 1988 Aug;72(2):520-9 [2840986.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1988 Fall;10(3):196-205 [2845831.001]
  • [Cites] J Gen Virol. 1989 May;70 ( Pt 5):1203-15 [2543775.001]
  • [Cites] J Gen Virol. 1992 Sep;73 ( Pt 9):2347-56 [1328491.001]
  • [Cites] J Immunol. 1993 Nov 1;151(9):4431-44 [8409411.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3259-64 [8241498.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):704-11 [7772506.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 20;12(8):651-7 [8744575.001]
  • [Cites] J Virol. 1996 Oct;70(10):6775-80 [8794315.001]
  • [Cites] Immunity. 1996 Dec;5(6):527-35 [8986713.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):863-71 [9064346.001]
  • [Cites] Acta Haematol. 1997;98(1):32-6 [9210911.001]
  • [Cites] Science. 1998 Jan 2;279(5347):84-8 [9417030.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1074-7 [9781644.001]
  • [Cites] J Virol. 1999 Jun;73(6):4651-61 [10233924.001]
  • [Cites] J Exp Med. 1999 Jul 5;190(1):75-89 [10429672.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):613-6 [10504449.001]
  • [Cites] J Virol Methods. 2005 Jun;126(1-2):91-100 [15847924.001]
  • [Cites] Mod Pathol. 2006 May;19(5):726-37 [16528368.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):149-57 [18434123.001]
  • [Cites] J Virol. 2008 Sep;82(17):8500-8 [18562537.001]
  • [Cites] J Virol. 2009 Jul;83(13):6484-93 [19386718.001]
  • [Cites] PLoS One. 2009;4(8):e6492 [19652715.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1378-85 [11070102.001]
  • (PMID = 20926565.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR018724; United States / NCI NIH HHS / CA / R01 CA139984; United States / NCI NIH HHS / CA / CA139984; United States / NCRR NIH HHS / RR / P20-RR018724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC3004345
  •  go-up   go-down


15. Liu JX, Chen JP, Tan W, Lin DX: [Association between mthfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun;16(3):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between mthfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia].
  • This study was aimed to investigate the association between mthfr gene polymorphisms and toxicity of HDMTX in acute lymphocytic leukemia patients.
  • The results showed that the toxicity of HDMTX to carriers of the variant allele at codon 677 (CT or TT) increased, as compared with individuals with the common CC genotype (OR = 3.75, 95% CI 1 - 14, p = 0.04).
  • In contrast, the toxicity of HDMTX to ALL patients with the variant allele at codon 1298 (AC or CC) decreased as compared with the common AA genotype carriers (OR = 0.12, 95% CI: 0.026 - 0.564, p = 0.007).
  • It is concluded that mthfr gene polymorphisms associate with the toxicity of HDMTX chemotherapy in acute lymphocytic leukemia.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549614.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Lal R, Prasad DK, Krishna P, Sikora SS, Poddar U, Yachha SK, Kumari N: Biliary atresia with a "cyst at porta": management and outcome as per the cholangiographic anatomy. Pediatr Surg Int; 2007 Aug;23(8):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cholangiographic anatomy was classified as; Group A (n = 7), type III BA with extrahepatic cyst; Group B (n = 2), type I or II BA with extrahepatic biliary cyst; and Group C (n = 4), type I or II BA with both extrahepatic and intrahepatic biliary cysts.
  • The remaining 45 patients were comprised of type III BA without a cyst.
  • All 45 patients with type III BA without a cyst were treated by a Kasai's PE.
  • There were three early post-operative deaths, all in patients with type III BA without cyst.
  • Of the remaining 42 patients with type III BA without a cyst, 27 (64.3%) had bile flow, 13 (31%) became jaundice free and 14 (33.3%) have had 1-2 episodes of post-operative cholangitis.
  • The outcome was most satisfactory in type I BA without intrahepatic cystic dilatation (Group B) in terms of achieving a jaundice free state and freedom from recurrent cholangitis.
  • The outcome in type III BA with extrahepatic cyst was comparable to type III BA without cyst.

  • Genetic Alliance. consumer health - Biliary Atresia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):32-6 [2005521.001]
  • [Cites] J Pediatr Surg. 1994 May;29(5):630-4 [8035271.001]
  • [Cites] J Formos Med Assoc. 1996 Jul;95(7):567-71 [8840762.001]
  • [Cites] J Pediatr Surg. 1990 Oct;25(10):1076-80; discussion 1081 [2262862.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):997-1000 [12861525.001]
  • [Cites] Radiology. 1998 Nov;209(2):465-9 [9807575.001]
  • [Cites] Pediatr Surg Int. 2006 Oct;22(10):803-7 [16947025.001]
  • [Cites] Eur J Pediatr Surg. 1999 Oct;9(5):340-2 [10584198.001]
  • [Cites] Surgery. 1975 Mar;77(3):384-90 [1124494.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] J Pediatr Surg. 2006 Dec;41(12 ):1973-5 [17161184.001]
  • [Cites] AJR Am J Roentgenol. 1994 Jan;162(1):167-71 [8273658.001]
  • [Cites] J Pediatr Surg. 2000 Dec;35(12 ):1771-4 [11101734.001]
  • [Cites] J Pediatr Surg. 1998 May;33(5):700-4 [9607471.001]
  • [Cites] Eur J Pediatr Surg. 1998 Jun;8(3):146-9 [9676396.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 May;36(5):608-12 [12717083.001]
  • [Cites] Surgery. 1974 Feb;75(2):228-32 [4840842.001]
  • [Cites] J Pediatr Surg. 1987 Jun;22(6):522-5 [3612442.001]
  • [Cites] Semin Pediatr Surg. 2005 Feb;14(1):42-8 [15770587.001]
  • (PMID = 17569062.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, Persing DH: Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol; 2010 Oct;48(10):3719-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.
  • A total of 2,296 unformed stool specimens, collected from seven study sites, were tested by Xpert C. difficile enrichment culture followed by cell culture cytotoxicity testing of the isolates (i.e., toxigenic culture with enrichment) and the study sites' standard C. difficile test methods.
  • All C. difficile strains were typed by PCR-ribotyping.
  • The Xpert C. difficile assay is a simple, rapid, and accurate method for detection of toxigenic C. difficile in unformed stool specimens and is minimally affected by strain type compared to EIA and GDH-based methods.
  • [MeSH-major] Bacteriological Techniques / methods. Clostridium Infections / diagnosis. Clostridium difficile / isolation & purification. Molecular Diagnostic Techniques / methods

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1645-51 [10572152.001]
  • [Cites] J Hosp Infect. 2009 Jun;72(2):111-8 [19386381.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4031-7 [12958221.001]
  • [Cites] J Clin Microbiol. 1986 Mar;23(3):622-3 [3082928.001]
  • [Cites] J Clin Microbiol. 1991 Nov;29(11):2639-42 [1774279.001]
  • [Cites] J Clin Microbiol. 1993 Mar;31(3):507-11 [8458943.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):1145-9 [16517916.001]
  • [Cites] Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18 [16965399.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1152-60 [17918076.001]
  • [Cites] Clin Microbiol Infect. 2007 Nov;13(11):1048-57 [17850341.001]
  • [Cites] Clin Infect Dis. 2007 Nov 15;45(10):1266-73 [17968819.001]
  • [Cites] J Clin Microbiol. 2007 Nov;45(11):3601-5 [17804652.001]
  • [Cites] Euro Surveill. 2007 Jun;12(6):E1-2 [17991399.001]
  • [Cites] Infect Control Hosp Epidemiol. 2008 Mar;29(3):197-202 [18241032.001]
  • [Cites] J Clin Microbiol. 2008 Apr;46(4):1523-5 [18256226.001]
  • [Cites] J Clin Microbiol. 2008 Jun;46(6):1996-2001 [18434563.001]
  • [Cites] N Engl J Med. 2008 Oct 30;359(18):1932-40 [18971494.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3833-5 [18784313.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3686-9 [18845820.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):373-8 [19073875.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):176-9 [19652187.001]
  • [Cites] J Clin Microbiol. 2009 Sep;47(9):3004-7 [19571021.001]
  • [Cites] J Clin Microbiol. 2009 Oct;47(10):3211-7 [19710274.001]
  • [Cites] J Clin Microbiol. 2009 Nov;47(11):3729-31 [19741082.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):270-3 [19853666.001]
  • [Cites] J Clin Microbiol. 2009 Dec;47(12):3846-50 [19846637.001]
  • [Cites] J Clin Microbiol. 2010 Jan;48(1):124-30 [19923482.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Feb;66(2):129-34 [20117349.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):603-5 [19955275.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):606-8 [20032256.001]
  • [Cites] J Clin Microbiol. 2010 Mar;48(3):889-93 [20071552.001]
  • [Cites] Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72 [19215193.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Nov;23(11):639-40 [12452289.001]
  • (PMID = 20702676.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953097
  •  go-up   go-down


18. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML: Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol; 2009 Jul;7(7):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited.
  • Hyperglycemia has been described as a common event occurring during acute lymphocytic leukemia chemotherapy.
  • Our goal was to compare clinical and laboratory findings between hyperglycemic episodes occurring during childhood acute lymphocytic leukemia induction chemotherapy.
  • There were no differences in clinical or laboratory variables among groups, although the majority of episodes occurred in pubescents, regardless of the type of glucocorticoid employed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Glucocorticoids / adverse effects. Hyperglycemia / chemically induced. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701154.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; EC 3.2.1.- / Amylases
  •  go-up   go-down


19. Dalmas DA, Tierney LA, Zhang C, Narayanan PK, Boyce RW, Schwartz LW, Frazier KS, Scicchitano MS: Effects of p38 MAP kinase inhibitors on the differentiation and maturation of erythroid progenitors. Toxicol Pathol; 2008 Dec;36(7):958-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To identify target cell populations affected, a differentiating primary liquid erythroid culture system using sca-1(+)cells from mouse bone marrow was developed and challenged with p38is SB-203580, SB-226882, and SB-267030.
  • Drug-related alterations in genes involved at different stages of erythropoiesis, cell-surface antigen expression (CSAE), burst-forming unit erythroid (BFU-E) colony formation, and cellular morphology (CM), growth (CG), and viability were evaluated.
  • [MeSH-minor] Animals. Antigens, Ly / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Bone Marrow Cells / drug effects. Cell Culture Techniques. Cell Survival / drug effects. Cells, Cultured. Colony-Forming Units Assay. Erythroid Precursor Cells / drug effects. GATA2 Transcription Factor / metabolism. Immunophenotyping. Male. Membrane Proteins / metabolism. Mice. Proto-Oncogene Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126791.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Ly; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / GATA2 Transcription Factor; 0 / Gata2 protein, mouse; 0 / Imidazoles; 0 / Ly6a protein, mouse; 0 / Membrane Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Pyridines; 0 / SB 203580; 0 / Tal1 protein, mouse; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


20. Hildebrandt P, Richards AM: Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol; 2008 Feb 4;101(3A):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension.
  • Although the current value of amino-terminal pro-B-type natriuretic peptides (NT-proBNP) to generally screen populations of "apparently well patients" remains promising but still undefined, the use of NT-proBNP to screen patients at high risk for heart disease (such as elderly patients, or patients with diabetes mellitus, hypertension, or known coronary artery disease) appears logical and is supported by data.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243853.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 19
  •  go-up   go-down


21. Ma X, Buffler PA, Wiemels JL, Selvin S, Metayer C, Loh M, Does MB, Wiencke JK: Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):1928-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia.
  • A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).
  • We evaluated the possible etiologic role of daycare attendance (a proxy measure for exposure to infectious agents) and infections during infancy in the Northern California Childhood Leukemia Study.
  • The magnitude of effect associated with the same number of child-hours was stronger for daycare attendance during infancy than for daycare attendance before diagnosis.
  • [MeSH-major] Child Day Care Centers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Child Care.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103439.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


22. Zhang Y, Wang Y, Huang L, Chen D, Tao Y, Yuan Z: Effects of cooking and storage on residues of cyadox in chicken muscle. J Agric Food Chem; 2005 Dec 14;53(25):9737-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat stabilities of cyadox (CYX) and its two metabolites, 1,4-bisdesoxycyadox (BDCYX) and quinoxaline-2-carboxylic acid (QCA), in water, cooking oil, and as incurred residues in chicken muscle were investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332123.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinoxalines; 65884-46-0 / cyadox
  •  go-up   go-down


23. Zhou J, Mauerer K, Farina L, Gribben JG: The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci; 2005;10:1581-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor microenvironment is essential for tumor cell proliferation, angiogenesis, invasion, and metastasis by providing survival signals and a sanctuary site for tumor cells, by secretion of growth factors, pro-angiogenesis factors and direct adhesion molecule interactions.
  • In this review, the morphological and molecular characteristics of microenvironment in various hematological malignancies including acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, lymphoma, chronic lymphocytic leukemia, and multiple myeloma are summarized and the molecular mechanisms of microenvironment contributing to leukemogenesis are elucidated.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769648.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Cyclohexanes; 0 / Cytokines; 0 / Matrix Metalloproteinase Inhibitors; 0 / Sesquiterpenes; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; EC 2.5.1.21 / Farnesyl-Diphosphate Farnesyltransferase
  • [Number-of-references] 154
  •  go-up   go-down


24. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT: Immunogenicity of Bcl-2 in patients with cancer. Blood; 2005 Jan 15;105(2):728-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers.
  • Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials.
  • Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]).
  • Additionally, we show that these Bcl-2-reactive T cells are indeed peptide-specific, cytotoxic effector cells.
  • [MeSH-minor] Acute Disease. Breast Neoplasms / immunology. Granzymes. HLA-A2 Antigen / metabolism. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Myeloid / immunology. Peptide Fragments / metabolism. Protein Binding. Serine Endopeptidases. T-Lymphocytes, Cytotoxic / immunology. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15367432.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


25. Airoldi I, Cocco C, Di Carlo E, Disarò S, Ognio E, Basso G, Pistoia V: Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res; 2006 Apr 15;66(8):3978-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.
  • The aim of this study was to investigate (i) whether the IL-12Rbeta2 gene is silenced in B-cell acute lymphoblastic leukemia (B-ALL) cells, and (ii) what the functional implications of such silencing for tumor growth are.
  • Here, we show that although mature B cells expressed both chains of the IL-12R, normal pro-B and pre-B cells failed to express the IL-12Rbeta2 chain.
  • Similarly, primary tumor cells from pediatric pro-B, early pre-B, and pre-B ALL (30 cases) did not express the IL-12Rbeta2 chain.
  • Such methylation was not detected in normal early B cells that when differentiated into mature B cells expressed the IL-12Rbeta2 gene.
  • Detection of IL-12Rbeta2 mRNA and protein in the tumorigenic 697 pre-B-ALL cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12).
  • [MeSH-major] Burkitt Lymphoma / genetics. DNA Methylation. Receptors, Interleukin / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / IL12RB2 protein, human; 0 / Il12rb2 protein, mouse; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-12
  •  go-up   go-down


26. van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Révész T, Staal FJ, van Dongen JJ: Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol; 2005 Nov 1;175(9):5912-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression.
  • The role of specific transcription factors in the initiation and regulation of Ig gene rearrangements has been studied extensively in mouse models, but data on normal human precursor B cell differentiation are limited.
  • We purified five human precursor B cell subsets, and assessed and quantified their IGH, IGK, and IGL gene rearrangement patterns and gene expression profiles.
  • Pro-B cells already massively initiate D(H)-J(H) rearrangements, which are completed with V(H)-DJ(H) rearrangements in pre-B-I cells.
  • Large cycling pre-B-II cells are selected for in-frame IGH gene rearrangements.
  • The first IGK/IGL gene rearrangements were initiated in pre-B-I cells, but their frequency increased enormously in small pre-B-II cells, and in-frame selection was found in immature B cells.
  • Transcripts of the RAG1 and RAG2 genes and earlier defined transcription factors, such as E2A, early B cell factor, E2-2, PAX5, and IRF4, were specifically up-regulated at stages undergoing Ig gene rearrangements.
  • Based on the combined Ig gene rearrangement status and gene expression profiles of consecutive precursor B cell subsets, we identified 16 candidate genes involved in initiation and/or regulation of Ig gene rearrangements.
  • These analyses provide new insights into early human precursor B cell differentiation steps and represent an excellent template for studies on oncogenic transformation in precursor B acute lymphoblastic leukemia and B cell differentiation blocks in primary Ab deficiencies.
  • [MeSH-minor] Adolescent. Cell Separation. Child. Child, Preschool. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2006 Jun 15;176(12):7787
  • (PMID = 16237084.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


27. Ran YC, Ao XX, Liu L, Fu YL, Tuo H, Xu F: [Distribution and drug resistance of pathogenic bacteria isolated from infected wounds of children after Wenchuan earthquake]. Zhonghua Er Ke Za Zhi; 2009 May;47(5):332-6; discussion 336-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acinetobacter baumanii was the most common organism isolated from wounds.
  • Drug sensitivity tests displayed that the isolated bacteria were highly resistant to common antibiotics.
  • One strain of Acinetobacter baumanii-calcoaceticus complex and six strains of Acinetobacter baumanii were resistant to all common antibiotics including imipenem/cilastatin.
  • CONCLUSION: Following the Wenchuan earthquake disaster, wound infection profiles of pediatric patients were significantly different, Acinetobacter baumanii was the main common organism isolated from wounds in contrast to the previous low isolation rate.


28. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J; 2010 Apr;159(4):532-538.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
  • BACKGROUND: Serial measurements of N-terminal pro-B type natriuretic peptide (NT-proBNP) provide prognostic information in patients with chronic heart failure (HF).
  • CONCLUSIONS: The Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study will test the hypothesis that therapy guided by NT-proBNP concentrations will be superior to standard of care HF management (www.clinicaltrials.gov identifier NCT00351390).

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20362709.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00351390
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


29. Obama K, Makishima H, Ishida F: Killer cell immunoglobulin-like receptor gene polymorphism in lymphoproliferative diseases of granular lymphocytes in a Japanese population. Leuk Lymphoma; 2010 Aug;51(8):1580-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Killer cell immunoglobulin-like receptor gene polymorphism in lymphoproliferative diseases of granular lymphocytes in a Japanese population.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Large Granular Lymphocytic / genetics. Lymphocytosis / genetics. Polymorphism, Genetic / genetics. Receptors, KIR / genetics
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. Case-Control Studies. Chronic Disease. Genotype. Humans. Polymerase Chain Reaction. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528243.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, KIR
  •  go-up   go-down


30. Liu YQ, Zhang YZ, Sun CY, Gao PJ: A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method. Am J Chin Med; 2005;33(4):671-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.
  • The antibacterial pharmacodynamics against E. coli of Chinese medicine (CM) Rhizoma coptidis (Coptis Root) and its formula Sanhuang, and the control antibiotics enoxacin, were analyzed by a concentration-killing curve (CKC) approach, and the novel parameters BC50 and r for antibacterial potency were proposed.
  • Using the agar plate method, about 400 cells of E. coli were evenly inoculated into LB agar plates containing a series of different concentrations of CM or antibiotic, and after a 24 hour incubation at 37 degrees C, all the viable colonies were enumerated.
  • This resulted in a sigmoid concentration-killing curve , in which No, that could be closely fitted (R2 > 0.9) with the function: N = 1 + e(r(x-BC50))/N0 in which N0, BC50 and r represent meaningfully inoculums size, median bactericidal concentration, and bactericidal intensity, respectively.
  • N modeled the survival of colony-forming units on each plate (CFU/plate) in a concentration series x of the drug.
  • The CKC was symmetrical about its single inflexion (BC50, N0/2).
  • Therefore theoretically, 2BC50 can replace MBC (minimum bactericidal concentration).
  • BC1 = BC50 + r/ln(N0-1), the drug concentration at r which only one colony survived, was the least critical value of MBC in CKC.
  • The parameters 2BC50 and BC1 agreed more closely with the definition of MBC, and were little affected by either the biochemical basis of the antibacterial or the inoculum's size (200-400 CFU/plate), and were determined by a multi-point curve.
  • As a result, these were more accurate, reproducible and practical as metrics than was the endpoint of MBC.
  • The two-dimensional CKC, involving BC50 and r, captures the intrinsic dynamics of the antibacterial effect of CM/strain versus concentration, and it is consistent with the Logistic equation of the bacterial growth curve in the format.
  • This verified approach has considerable value as a tool for the accurate and proper administration of CM.
  • The CKC of CM, different from that of antibiotics, is likely to be the resultant force of each ingredient in certain CM, which provides a clue to solve the problem of antibiotic resistance.
  • [MeSH-major] Escherichia coli / drug effects. Medicine, Chinese Traditional. Microbial Sensitivity Tests / methods. Models, Biological
  • [MeSH-minor] Coptis. In Vitro Techniques. Plant Bark. Reproducibility of Results. Rheum

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173540.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


31. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH: Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther; 2010;12(4):R154
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis (RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic site.
  • The RRs were elevated in RA patients across all common sites of osteoporotic fracture: hip (1.62, 95% CI 1.43 to 1.84), wrist (1.15, 95% CI 1.00 to 1.32), pelvis (2.02, 95% CI 1.77 to 2.30), and humerus (1.51, 95% CI 1.27 to 1.84).

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3790-8 [17136752.001]
  • [Cites] Arthritis Rheum. 2006 Oct;54(10):3104-12 [17009229.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906 [17870034.001]
  • [Cites] J Rheumatol. 2007 Oct;34(10):1971-5 [17896806.001]
  • [Cites] Clin Rheumatol. 2008 May;27(5):565-72 [17909741.001]
  • [Cites] Mod Rheumatol. 2008;18(2):170-6 [18297237.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1952-8 [18285417.001]
  • [Cites] Am Heart J. 2008 Aug;156(2):336-41 [18657665.001]
  • [Cites] Rheumatol Int. 2008 Sep;28(11):1143-50 [18446340.001]
  • [Cites] J Rheumatol. 2008 Sep;35(9):1704-8 [18634160.001]
  • [Cites] Arthritis Res Ther. 2008;10(4):R95 [18717997.001]
  • [Cites] Ann Rheum Dis. 2009 Mar;68(3):373-6 [18408246.001]
  • [Cites] Arthritis Res Ther. 2008;10(6):R128 [18986531.001]
  • [Cites] J Clin Rheumatol. 2009 Jun;15(4):155-60 [19363452.001]
  • [Cites] Menopause. 2009 Sep-Oct;16(5):950-5 [19387415.001]
  • [Cites] Semin Arthritis Rheum. 2009 Oct;39(2):116-22 [18585759.001]
  • [Cites] BMC Public Health. 2009;9:344 [19761614.001]
  • [Cites] JAMA. 2009 Nov 25;302(20):2214-21 [19934422.001]
  • [Cites] Curr Osteoporos Rep. 2009 Dec;7(4):134-9 [19968917.001]
  • [Cites] Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13 [20464374.001]
  • [Cites] Arthritis Rheum. 2000 Mar;43(3):522-30 [10728744.001]
  • [Cites] J Rheumatol. 2000 Nov;27(11):2582-9 [11093437.001]
  • [Cites] Rheum Dis Clin North Am. 2001 May;27(2):283-303 [11396093.001]
  • [Cites] Am J Epidemiol. 2001 Nov 1;154(9):854-64 [11682368.001]
  • [Cites] Ann Rheum Dis. 2003 Apr;62(4):347-9 [12634235.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):917-26 [12687533.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1066-76 [15077288.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1267-71 [15252210.001]
  • [Cites] Arthritis Rheum. 1984 Dec;27(12):1353-61 [6508860.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Rheumatol. 1991 Jun;18(6):804-8 [1895260.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] J Clin Epidemiol. 1992 Jul;45(7):703-14 [1619449.001]
  • [Cites] J Rheumatol. 1993 Oct;20(10):1666-9 [8295176.001]
  • [Cites] Ann Rheum Dis. 1994 Jan;53(1):18-23 [8311549.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Sep 15;19(18):2117-21 [7825055.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):767-73 [7862179.001]
  • [Cites] J Bone Miner Res. 1995 Feb;10(2):257-63 [7754805.001]
  • [Cites] Lancet. 1996 Jul 20;348(9021):145-9 [8684153.001]
  • [Cites] Bone. 1998 Aug;23(2):75-81 [9701464.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220-1 [10421309.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):323-37 [15862718.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):581-9 [15616758.001]
  • [Cites] Arch Intern Med. 2005 Jun 13;165(11):1293-7 [15956010.001]
  • [Cites] J Crit Care. 2005 Mar;20(1):12-9 [16015512.001]
  • [Cites] Osteoporos Int. 2005 Oct;16(10):1263-71 [15702263.001]
  • [Cites] J Bone Miner Res. 2007 Jul;22(7):1088-95 [17419681.001]
  • (PMID = 20682035.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR056215; United States / NIAMS NIH HHS / AR / P60 AR047782; United States / NIDCR NIH HHS / DE / R21 DE018750; United States / NIAMS NIH HHS / AR / K24 AR055989; United States / NIAMS NIH HHS / AR / AR055989; United States / NIAMS NIH HHS / AR / T32 AR 055885
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945054
  •  go-up   go-down


32. Winkel TA, Schouten O, Hoeks SE, Flu WJ, Hampton D, Kirchhof P, van Kuijk JP, Lindemans J, Verhagen HJ, Bax JJ, Poldermans D: Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. Am Heart J; 2010 Jun;159(6):1108-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac risk factors, inflammatory status, and left ventricular function (LVF; N-terminal pro-B-type natriuretic peptide and echocardiography) were assessed.
  • CONCLUSION: New-onset perioperative arrhythmias are common after vascular surgery.

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20569727.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Dieplinger B, Haltmayer M, Poelz W, Mueller T: Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study. Clin Chim Acta; 2009 Oct;408(1-2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have previously demonstrated that adiponectin is associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with peripheral artery disease (PAD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646980.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Biomarkers
  •  go-up   go-down


34. Pawelec K, Trzcińska A, Siennicka J, Malinowska I, Litwińska B: [Epstein-Barr infections in children with acute leukaemia. Preliminary report]. Med Wieku Rozwoj; 2008 Jan-Mar;12(1):485-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr infections in children with acute leukaemia. Preliminary report].
  • INTRODUCTION: Epstein-Barr virus (EBV) infection is common all over the world.
  • THE AIM: of this study was to evaluate the effectiveness of laboratory methods used to detect EBV and to monitor EBV infections in children with acute leukaemia.
  • MATERIALS AND METHODS: we conducted the study on 30 children with acute leukaemia.
  • Specific IgM and IgG antibodies for viral capsid antigen (VCA), nuclear (EBN) and early antigen (EA) were tested by ELSA.
  • Results of serological investigations indicated the type of EBV infection in our patients.
  • 3. In order to assess the effectiveness of serological and molecular methods in evaluation of EBV infection type in children with acute leukaemia, it is necessary to investigate a larger group of patients and taken at least three times.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663268.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


35. Deshpande VS, Kehrer JP: Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol; 2006 Aug 1;214(3):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nordihydroguaiaretic acid (NDGA), a general lipoxygenase (LOX) enzyme inhibitor, induces apoptosis independently of its activity as a LOX inhibitor in murine pro-B lymphocytes (FL.12 cells) by a mechanism that is still not fully understood.
  • [MeSH-minor] Acetylcysteine / pharmacology. Animals. Caspase 3. Caspases / metabolism. Cell Line. Cytochromes c / metabolism. Dithiothreitol / pharmacology. Electrophoresis, Polyacrylamide Gel. Enzyme Inhibitors / pharmacology. Mice. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473382.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Lipoxygenase Inhibitors; 7BO8G1BYQU / Masoprocol; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; T8ID5YZU6Y / Dithiothreitol; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


36. Lalani M, Rhee JC, Gutkin DW, Matin K, Ahmad J: Uncommon presentations of some common malignancies: Case 3. Chronic lymphocytic leukemia involving the colon and presenting with perforation. J Clin Oncol; 2005 Feb 20;23(6):1315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon presentations of some common malignancies: Case 3. Chronic lymphocytic leukemia involving the colon and presenting with perforation.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Abdomen, Acute / surgery. Aged. Colectomy. Humans. Male

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718331.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Grzybowska-Izydorczyk O, Smolewski P: [The role of the inhibitor of apoptosis protein (IAP) family in hematological malignancies]. Postepy Hig Med Dosw (Online); 2008 Feb 14;62:55-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The apoptotic mode of cell death is a major regulatory process in all complex organisms.
  • The low proliferative index and slow accumulation of malignant cells in chronic lymphocytic leukemia (CLL), the most frequent type of leukemia in Europe and North America, suggests that the disease is caused by a defect in apoptosis regulation.
  • Classical apoptosis is executed through the activation of caspases, cysteine proteases which are regulated by a number of pro- and anti-apoptotic proteins.
  • The IAP family inhibits apoptosis by binding to specific caspases and possibly by other mechanisms.
  • Overexpression of several IAPs has been detected in various hematological malignancies, including acute leukemias, myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), and many types of lymphoid malignancies, such as chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
  • It seems that overexpression of XIAP in acute myeloid leukemia (AML) and survivin in acute lymphoblastic leukemia (ALL) and DLBCL could become a new unfavorable prognostic factor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283236.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins
  • [Number-of-references] 67
  •  go-up   go-down


38. Wang H, Li D, Li JT, Wang XL, Hao LC: [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):739-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia].
  • This study was purposed to investigate the possible side effects of L-asparaginase (L-ASP) in the treatment of patients with acute lymphoblastic leukemia (ALL) and to explore the correlation of these side effects at different therapeutic stages by means of retrospective analysis, so as to reduce the incidence of side effects and improve the safety of chemotherapy and the long-term survival of patients.
  • The results showed that allergic response, diabetes and drug-induced liver disease happened more frequently during maintenance therapy than during remission induction therapy, while defibrination, abnormal hemagglutinin, acute pancreatitis, hypoproteinemia, gastrointestinal reaction and infectious shock were observed more during remission induction therapy than those at maintenance therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549398.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


39. Truong QA, Siegel E, Karakas M, Januzzi JL Jr, Bamberg F, Mahabadi AA, Dasdemir S, Brady TJ, Bergmann A, Kunde J, Nagurney JT, Hoffmann U, Koenig W: Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial. Clin Chem; 2010 Apr;56(4):651-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined associations between amino-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM) concentrations and cardiac chamber volumes in chest pain patients without heart failure by use of computed tomography (CT).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2000 Apr;21(2):138-67 [10782362.001]
  • [Cites] J Intern Med. 2010 Jan;267(1):119-29 [19570053.001]
  • [Cites] Circulation. 2003 May 6;107(17):2207-12 [12695291.001]
  • [Cites] Heart. 2003 Jul;89(7):745-51 [12807847.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):234-6 [14709661.001]
  • [Cites] J Am Coll Cardiol. 2004 Jan 7;43(1):55-60 [14715184.001]
  • [Cites] Peptides. 2004 Aug;25(8):1369-72 [15350706.001]
  • [Cites] Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 [2520314.001]
  • [Cites] Endocrinology. 1993 May;132(5):1961-70 [8477647.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1105-9 [8097801.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60 [8387282.001]
  • [Cites] FEBS Lett. 1994 Jan 24;338(1):6-10 [8307158.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 30;201(3):1160-6 [8024557.001]
  • [Cites] Circulation. 1994 Jul;90(1):195-203 [8025996.001]
  • [Cites] J Clin Invest. 1996 May 15;97(10):2370-6 [8636418.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1823-9 [16099941.001]
  • [Cites] Clin Chem. 2006 May;52(5):827-31 [16543387.001]
  • [Cites] J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24 [16979009.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] J Card Fail. 2007 Feb;13(1):42-9 [17339002.001]
  • [Cites] J Am Coll Cardiol. 2007 Apr 10;49(14):1525-32 [17418290.001]
  • [Cites] J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80 [17996563.001]
  • [Cites] Clin Biochem. 2008 Mar;41(4-5):222-6 [18035345.001]
  • [Cites] Clin Chem Lab Med. 2008;46(2):204-11 [18076360.001]
  • [Cites] Clin Chim Acta. 2008 Jun;392(1-2):41-5 [18387360.001]
  • [Cites] J Am Coll Cardiol. 2008 May 13;51(19):1857-64 [18466800.001]
  • [Cites] Eur Radiol. 2008 Aug;18(8):1625-34 [18446346.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):305-11 [18628102.001]
  • [Cites] Int J Cardiol. 2008 Aug 18;128(2):244-9 [17673312.001]
  • [Cites] Circ J. 2008 Nov;72(11):1777-86 [18832779.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):80-7 [19332340.001]
  • [Cites] J Am Coll Cardiol. 2009 May 5;53(18):1642-50 [19406338.001]
  • [Cites] J Am Coll Cardiol. 2009 May 12;53(19):1783-90 [19422985.001]
  • [Cites] Regul Pept. 2009 Jun 5;155(1-3):33-8 [19328828.001]
  • [Cites] JAMA. 2009 Jul 1;302(1):49-57 [19567439.001]
  • [Cites] J Am Coll Cardiol. 2009 Jul 21;54(4):357-64 [19608034.001]
  • [Cites] Heart Fail Clin. 2009 Oct;5(4):489-500 [19631174.001]
  • [Cites] Heart. 2003 Feb;89(2):150-4 [12527664.001]
  • (PMID = 20185624.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32HL076136; United States / NHLBI NIH HHS / HL / L30 HL093806-01; United States / NHLBI NIH HHS / HL / T32 HL076136; United States / NHLBI NIH HHS / HL / L30HL093896; United States / NHLBI NIH HHS / HL / R01 HL080053; United States / NHLBI NIH HHS / HL / L30 HL093806; United States / NHLBI NIH HHS / HL / K23 HL098370; United States / NHLBI NIH HHS / HL / HL093806-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / proadrenomedullin; 114471-18-0 / Natriuretic Peptide, Brain; 148498-78-6 / Adrenomedullin
  • [Other-IDs] NLM/ NIHMS251716; NLM/ PMC2997388
  •  go-up   go-down


40. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer; 2005 May 23;92(10):1881-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
  • It has proved beneficial in treating patients with chronic myeloid leukaemia (CML).
  • The activity of IM in the blastic crisis of CML and against various myeloma cell lines suggests that this drug may also target other cellular components.
  • In the light of the important role of telomerase in malignant transformation, we evaluated the effect of IM on telomerase activity (TA) and regulation in various malignant cell lines.
  • Imatinib mesylate caused a dose-dependent inhibition of TA (up to 90% at a concentration of 15 microM IM) in c-kit-expressing SK-N-MC (Ewing sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer) and HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells), which do not express c-kit, BCR-ABL or PDGF-R.
  • The inhibition of proliferation was associated with a decrease in the S-phase of the cell cycle and an accumulation of cells in the G2/M phase.
  • This study demonstrates an additional cellular target of IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation.
  • [MeSH-minor] Animals. Benzamides. Cell Proliferation. Dose-Response Relationship, Drug. Down-Regulation. Fanconi Anemia / pathology. Humans. Imatinib Mesylate. Mice. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / pharmacology. Tumor Cells, Cultured


41. Godschalk PC, Gilbert M, Jacobs BC, Kramers T, Tio-Gillen AP, Ang CW, Van den Braak N, Li J, Verbrugh HA, Van Belkum A, Endtz HP: Co-infection with two different Campylobacter jejuni strains in a patient with the Guillain-Barré syndrome. Microbes Infect; 2006 Jan;8(1):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consequently, not all C. jejuni strains isolated from the faeces of a GBS patient are involved in the pathogenesis of GBS per se.
  • Furthermore, this is the first report in which cross-reactivity of antibodies to asialo-GM2 and to the LOS of a C. jejuni strain from a GBS patient has been demonstrated.


42. Gaukrodger N, Mayosi BM, Imrie H, Avery P, Baker M, Connell JM, Watkins H, Farrall M, Keavney B: A rare variant of the leptin gene has large effects on blood pressure and carotid intima-medial thickness: a study of 1428 individuals in 248 families. J Med Genet; 2005 Jun;42(6):474-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common polymorphisms of LEP have been associated with obesity, but their association with cardiovascular disease has been little studied.
  • We have examined the impact of both common and rare polymorphisms of the LEP gene on blood pressure (BP), subclinical atherosclerosis as measured by carotid intima-medial thickness (CIMT), and body mass index (BMI) in a large family study.
  • RESULTS: The polymorphisms typed captured all common haplotypes present at LEP.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]
  • [Cites] Obes Res. 1997 Jan;5(1):30-5 [9061713.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):259-66 [9634505.001]
  • [Cites] Hum Mol Genet. 1998 Oct;7(11):1745-51 [9736776.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3239-42 [9745435.001]
  • [Cites] Hypertension. 1999 May;33(5):1111-7 [10334796.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):279-92 [10631157.001]
  • [Cites] Ann Hum Genet. 1999 May;63(Pt 3):227-34 [10738535.001]
  • [Cites] J Hum Hypertens. 2000 Sep;14(9):573-9 [10980589.001]
  • [Cites] Diabetes. 2000 Dec;49(12):2196-200 [11118025.001]
  • [Cites] Am J Hypertens. 2001 Feb;14(2):91-7 [11243313.001]
  • [Cites] Ann Hum Genet. 2000 Sep;64(Pt 5):391-4 [11281277.001]
  • [Cites] Hypertension. 2001 May;37(5):1236-41 [11358934.001]
  • [Cites] J Hypertens. 2001 May;19(5):871-7 [11393669.001]
  • [Cites] Mol Cell Biochem. 2001 Aug;224(1-2):53-67 [11693200.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1706-9 [11926895.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2909-12 [12050272.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):544-8 [12110843.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1963-71 [12473259.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1903-13 [12493255.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):112-7 [14615386.001]
  • [Cites] Circulation. 2004 Mar 9;109(9):1089-94 [14993130.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):421-3 [15026459.001]
  • [Cites] Science. 2004 Aug 6;305(5685):869-72 [15297675.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):220-30 [15197684.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2691-7 [15345705.001]
  • [Cites] Hypertension. 1989 Jun;13(6 Pt 2):884-9 [2737726.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1158-9 [8097848.001]
  • [Cites] Circulation. 1993 Jul;88(1):20-8 [8319334.001]
  • [Cites] Genet Epidemiol. 1993;10(3):145-58 [8349098.001]
  • [Cites] Diabetes Care. 1999 Nov;22(11):1851-7 [10546019.001]
  • [Cites] Circulation. 1995 Oct 15;92(8):2127-34 [7554192.001]
  • [Cites] Diabetes. 1996 May;45(5):679-82 [8621022.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • (PMID = 15937081.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400874; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ PMC1736073
  •  go-up   go-down


43. Melchers F: Starting at the end. Eur J Immunol; 2007 Nov;37 Suppl 1:S125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After more than 40 years in immunology, I have moved "backwards" over mature B cells, immature B cells, precursor B cells and lymphocyte progenitors to pluripotent hematopoietic stem cells.
  • Initially it was an intellectual exercise to trace the unknown progenitor of known B-lineage cells; now it has become an experimental approach - to de- and re-differentiate B-lineage cells to earlier differentiation stages and to other lineages of hematopoietic cells.
  • [MeSH-major] Allergy and Immunology / history. B-Lymphocytes / cytology. Cell Differentiation / immunology. Hematopoietic Stem Cells / cytology. Precursor Cells, B-Lymphoid / cytology
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Lineage / immunology. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972356.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies
  • [Personal-name-as-subject] Melchers F
  •  go-up   go-down


44. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, Krishnamoorthy V, Bhasin M, Capobianco AJ, Kelliher MA: Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol; 2006 Nov;26(21):8022-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
  • Recent work with mouse models and human leukemic samples has shown that gain-of-function mutation(s) in Notch1 is a common genetic event in T-cell acute lymphoblastic leukemia (T-ALL).
  • To identify Notch1 target genes in leukemia, we developed mouse T-cell leukemic lines that express intracellular Notch1 in a doxycycline-dependent manner.
  • Using gene expression profiling and chromatin immunoprecipitation, we identified c-myc as a novel, direct, and critical Notch1 target gene in T-cell leukemia. c-myc mRNA levels are increased in primary mouse T-cell tumors that harbor Notch1 mutations, and Notch1 inhibition decreases c-myc mRNA levels and inhibits leukemic cell growth.
  • Consistent with these findings, retroviral insertional mutagenesis screening of our T-cell leukemia mouse model revealed common insertions in either notch1 or c-myc genes.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 May 13;280(19):19331-42 [15743767.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7 [16751266.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Future Oncol. 2005 Aug;1(4):511-9 [16556027.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3023-31 [16407836.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):273-85 [10594030.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):17211-20 [10747963.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35734-7 [10940313.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):138-44 [11248806.001]
  • [Cites] Oncogene. 2001 Jun 28;20(29):3897-905 [11439353.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7761-74 [11604511.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2179-81 [11679632.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):110-9 [11783997.001]
  • [Cites] Genes Dev. 2002 Jun 1;16(11):1397-411 [12050117.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7812-9 [12391150.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44754-9 [12223485.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5834-41 [12794108.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23196-203 [12682059.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2896-903 [12960312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3338-45 [14766969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4936-41 [15044701.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):24986-93 [15067010.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8813-22 [15456857.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1994 Dec 2;79(5):885-92 [8001125.001]
  • [Cites] Development. 1995 Aug;121(8):2633-44 [7671825.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Immunity. 1998 Dec;9(6):777-86 [9881968.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):518-22 [10206645.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):167-71 [10322160.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):5025-35 [10373552.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2112-20 [10473095.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):509-20 [15546612.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9313-9 [15611067.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7159-68 [16103066.001]
  • (PMID = 16954387.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899; United States / NCI NIH HHS / CA / CA-096889
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Enzyme Inhibitors; 0 / Myc protein, mouse; 0 / Notch1 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptor, Notch1; 0 / Tal1 protein, mouse; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC1636748
  •  go-up   go-down


45. Hochman E, Kinston S, Harmelin A, Göttgens B, Izraeli S: The SCL 3' enhancer responds to Hedgehog signaling during hemangioblast specification. Exp Hematol; 2006 Dec;34(12):1643-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cell leukemia (SCL), a basic helix-loop-helix (bHLH) transcription factor, is essential for the specification and function of the hemangioblast.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157160.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0800784
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Gli protein, mouse; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 0 / Zinc Finger Protein GLI1
  •  go-up   go-down


46. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K: Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol; 2010 Oct;38(10):885-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
  • OBJECTIVE: Cytotoxic ligands are involved in tumor immunity and graft-vs.-leukemia effect after allogeneic stem cell transplantation for leukemia.
  • To clarify the susceptibility of T-cell acute lymphoblastic leukemia (T-ALL) to tumor immunity, sensitivity to recombinant human soluble Fas ligand (rhsFasL) and tumor necrosis factor-related apoptosis-inducing ligand (rhsTRAIL) was determined.
  • MATERIALS AND METHODS: Sensitivity to rhsFasL and rhsTRAIL and cell surface expression of their receptors were tested in T-ALL cell lines (n = 7) and patients' samples (n = 17) and compared with those in B-precursor ALL cell lines (n = 30).
  • Expression of components of the death-inducing signaling complex and the TRAIL receptor genes (DR4/DR5), and the methylation status and promoter activity of the DR4/DR5 gene were tested in T-ALL cell lines.
  • RESULTS: T-ALL cell lines showed higher level of Fas expression and higher sensitivity to rhsFasL than did B-precursor ALL cell lines.
  • Despite comparable expression of components of death-inducing signaling complex, cell lines and patients' samples of T-ALL showed TRAIL-resistance associated with low cell surface expression of DR4/DR5.
  • Gene expression of DR4/DR5 in T-ALL cell lines was significantly lower than that in B-precursor ALL cell lines, and the methylation status of the gene promoter in T-ALL cell lines was associated with the gene expression level at least for DR4.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Fas Ligand Protein / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Antigens, CD95 / metabolism. Cell Line, Tumor. Cells, Cultured. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Drug Resistance. Flow Cytometry. Gene Expression / drug effects. Humans. Immunoblotting. Jurkat Cells. Luciferases / genetics. Luciferases / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20670671.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Fas Ligand Protein; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.13.12.- / Luciferases
  •  go-up   go-down


47. Forester CM, Braunreiter CL, Yaish H, Hedlund GL, Afify Z: Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia. Pediatr Radiol; 2009 Nov;39(11):1230-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.
  • In children, leukemia is the most common malignancy, and approximately 75% of leukemias are acute lymphoblastic leukemia (ALL).
  • Central nervous system leukemia is found at diagnosis in fewer than 5% of children with ALL.
  • Leukemic intracranial masses have been described with acute myeloid leukemia, but ALL presenting as a mass lesion is rare.
  • We describe a unique case of an intracranial confirmed precursor B cell (pre-B) ALL mass in a 13-year-old girl that was diagnosed by brain CT, MRI and cerebral angiography, and confirmed by biopsy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Angiography / methods. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tomography, X-Ray Computed / methods


48. Fujiwara T, Lee HY, Sanalkumar R, Bresnick EH: Building multifunctionality into a complex containing master regulators of hematopoiesis. Proc Natl Acad Sci U S A; 2010 Nov 23;107(47):20429-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The demonstration that ETO2 and LMO2 exert qualitatively distinct functions at endogenous loci illustrates how components of complexes containing master developmental regulators can impart the capacity to regulate unique cohorts of target genes, thereby diversifying complex function.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8811-6 [12857954.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):476-81 [14695898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):980-5 [14715908.001]
  • [Cites] Methods Mol Biol. 2004;284:129-46 [15173613.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6470-83 [11533236.001]
  • [Cites] Curr Opin Hematol. 2001 Jul;8(4):197-200 [11561155.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4268-79 [12024038.001]
  • [Cites] J Exp Med. 2002 Jun 3;195(11):1387-95 [12045237.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):281-96 [12566412.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] Nat Genet. 1992 May;1(2):92-8 [1302015.001]
  • [Cites] Nature. 1994 Sep 15;371(6494):221-6 [8078582.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Cell. 1996 Jul 12;86(1):47-57 [8689686.001]
  • [Cites] Cell. 1996 Sep 20;86(6):917-27 [8808627.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):474-8 [8945476.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1642-51 [9032291.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] Genes Dev. 1997 Oct 15;11(20):2729-40 [9334334.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13707-12 [9391090.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5129-40 [9724649.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):219-28 [10078204.001]
  • [Cites] Blood. 1999 Jul 1;94(1):87-96 [10381501.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3136-47 [15297311.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):453-62 [15694345.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2367-78 [15920470.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2354-66 [15920471.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(23):10235-50 [16287841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17065-70 [16286657.001]
  • [Cites] EMBO J. 2006 Jan 25;25(2):357-66 [16407974.001]
  • [Cites] Biochem J. 2006 Oct 15;399(2):297-304 [16800816.001]
  • [Cites] Development. 2006 Dec;133(24):4913-23 [17108004.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Genes Dev. 2007 Apr 15;21(8):942-55 [17437998.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(12):4551-65 [17438135.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5230-3 [17339418.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] Cell. 2008 Feb 22;132(4):631-44 [18295580.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6234-47 [18710942.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6681-94 [18779319.001]
  • [Cites] Cell Stem Cell. 2009 Feb 6;4(2):180-6 [19200805.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2191-201 [19011221.001]
  • [Cites] J Biol Chem. 2009 Oct 23;284(43):29310-9 [19654328.001]
  • [Cites] Annu Rev Genet. 2009;43:559-99 [19886812.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):667-81 [19941826.001]
  • [Cites] Genome Res. 2009 Dec;19(12):2172-84 [19887574.001]
  • [Cites] Mol Cell. 2009 Dec 25;36(6):984-95 [20064464.001]
  • [Cites] EMBO J. 2010 Jan 20;29(2):442-56 [19927129.001]
  • [Cites] EMBO J. 2010 Jan 20;29(2):457-68 [20010697.001]
  • [Cites] Mol Cell Biol. 2010 Apr;30(7):1852-63 [20123979.001]
  • [Cites] J Biol Chem. 2010 Oct 8;285(41):31087-93 [20670937.001]
  • [Cites] Science. 2003 Oct 17;302(5644):415-9 [14564000.001]
  • (PMID = 21059912.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE24359
  • [Grant] United States / NIDDK NIH HHS / DK / DK68634; United States / NIDDK NIH HHS / DK / R01 DK050107; United States / NIDDK NIH HHS / DK / DK50107; United States / NIDDK NIH HHS / DK / R01 DK068634; United States / NIDDK NIH HHS / DK / R37 DK050107; United States / NIDDK NIH HHS / DK / R56 DK068634
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / LDB1 protein, human; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Multiprotein Complexes; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / RUNX1T1 protein, human; 0 / Transcription Factors; 135471-20-4 / TAL1 protein, human
  • [Other-IDs] NLM/ PMC2996669
  •  go-up   go-down


49. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES, Schindler J: A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Dec;31(12):936-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children.
  • Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with pre-B ALL.
  • CONCLUSIONS: Combotox can be safely administered to children with refractory leukemia.
  • [MeSH-major] Immunotoxins / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ricin / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875969.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / CD22 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 9009-86-3 / Ricin
  •  go-up   go-down


50. Forestier E, Gauffin F, Andersen MK, Autio K, Borgström G, Golovleva I, Gustafsson B, Heim S, Heinonen K, Heyman M, Hovland R, Johannsson JH, Kerndrup G, Rosenquist R, Schoumans J, Swolin B, Johansson B, Nordgren A, Nordic Society of Pediatric Hematology and Oncology, Swedish Cytogenetic Leukemia Study Group, NOPHO Leukemia Cytogenetic Study Group: Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer; 2008 Feb;47(2):149-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature.
  • Although dic(9;20)(p13.2;q11.2) is a characteristic abnormality in childhood B-cell precursor acute lymphoblastic leukemias (BCP ALL), little is known about its clinical impact or the type and frequency of additional aberrations it may occur together with.
  • Consistent immunophenotypic features of the Nordic cases included positivity for HLA-DR, CD10, CD19, CD20, and CD22 and negativity for T-cell and myeloid markers; no detailed immunophenotypes were reported for the previously published cases.
  • The median patient age was 3 years, the female/male ratio was 2.0, the median white blood cell count was 24 x 10(9)/l, 11% had central nervous system involvement, and 5% had a mediastinal mass at diagnosis.
  • Thus, although relapses are quite common, postrelapse treatment of many patients is successful.
  • [MeSH-major] Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Cytogenetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17990329.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


56. Ma J, Sun H, Chen SM, Liu LX, Chen SQ, Liu YF, Xie XS, Meng XL, Deng M, Zhang QT, Li T: [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia].
  • The aim of this study was to explore the clinical features and survival of adult patients with CD20 positive B-lineage acute lymphoblastic leukemia (B-ALL).
  • The results showed that among 119 cases, CD20 positive B-ALL accounted for 40 cases (33.61%), CD20 negative B-ALL patents accounted for 79 cases (66.39), the percentage of male patients in CD20 positive and negative groups were 72.50% and 50.63%, the leukocyte counts at diagnosis in these two groups were (27.35+/-30.29)x10(9)/L and (0.11+/-81.72)x10(9)/L, respectively, there were significant differences (p<0.05), whereas the distribution of age, infiltration of liver, spleen, lymph nodes and central nervous system, the hemoglobin and platelet levels, the expression of myeloid lineage marker, the incidence of Ph chromosome, the ratio of hyperdiploid and normal karyotype, the complete remission rate within 4 weeks, induction death rate and relapse rate and so on in CD20 positive and negative groups showed no significant differences (p>0.05).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416193.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


57. Sabbattini P, Dillon N: The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development. Semin Immunol; 2005 Apr;17(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development.
  • The lambda5 and VpreB genes encode the components of the surrogate light-chain, which forms part of the pre-B cell receptor.
  • Activation of the genes in pro-B cells depends on the combined effects of early B cell factor (EBF) and the E2A factors E12 and E47.
  • Silencing of lambda5 expression in mature B cells occurs through the action of Ikaros on the gene promoter where it may compete for binding of EBF and initiate the formation of a silent chromatin structure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737573.001).
  • [ISSN] 1044-5323
  • [Journal-full-title] Seminars in immunology
  • [ISO-abbreviation] Semin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Membrane Glycoproteins; 0 / Transcription Factors
  • [Number-of-references] 56
  •  go-up   go-down


58. Goei D, Flu WJ, Hoeks SE, Galal W, Dunkelgrun M, Boersma E, Kuijper R, van Kuijk JP, Winkel TA, Schouten O, Bax JJ, Poldermans D: The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients. Anesth Analg; 2009 Nov;109(5):1403-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
  • INTRODUCTION: N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts adverse cardiac outcome in patients undergoing vascular surgery.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843778.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hemoglobins; 0 / Peptide Fragments; 0 / Troponin T; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


59. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG: The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J; 2006 Oct;27(19):2353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
  • AIMS: To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of major structural heart disease (MSHD) in patients with atrial fibrillation (AF) compared with those with sinus rhythm (SR) using receiver operator characteristic (ROC) analysis.
  • AF, a common finding in HF and MSHD, is also associated with raised plasma NT-proBNP.
  • [MeSH-major] Atrial Fibrillation / blood. Heart Failure / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood
  • [MeSH-minor] Aged. Echocardiography. Female. Humans. Male. Predictive Value of Tests. Regression Analysis. Ventricular Dysfunction, Left / diagnosis


60. MacKinnon N, Ridgway J, Crowell KJ, Macdonald PM: Aluminum binding to phosphatidylcholine lipid bilayer membranes: aluminum exchange lifetimes from 31P NMR spectroscopy. Chem Phys Lipids; 2006 Feb;139(2):85-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the temperature range from 5 to 35 degrees C all three exchange rate constants increased by roughly an order of magnitude from k approximately 1-2 to 10-14s(-1), exhibiting Arrhenius behavior with activation energies on the order of 30-45 kJ mol(-1) and correspondingly positive enthalpies of activation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336955.001).
  • [ISSN] 0009-3084
  • [Journal-full-title] Chemistry and physics of lipids
  • [ISO-abbreviation] Chem. Phys. Lipids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Lipid Bilayers; 0 / Membranes, Artificial; 0 / Phosphatidylcholines; 0 / Phosphorus Isotopes; CPD4NFA903 / Aluminum
  •  go-up   go-down


61. Chang PY, Draheim K, Kelliher MA, Miyamoto S: NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res; 2006 Jun 15;66(12):6008-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells.
  • We recently showed that a subset of human T acute lymphoblastic leukemia (T-ALL) cell lines expresses low basal levels of p50, a nuclear factor-kappaB (NF-kappaB)/Rel family member, resulting in their capacity to activate the atypical p65:cRel complex rather than the classic p50:p65 dimer.
  • When TAL1 expression is reduced in CEM T leukemia cells, basal NFKB1 expression is increased, and the levels of p65:cRel complex and transcription of its target gene, such as intercellular adhesion molecule-1 (ICAM-1), are reduced in response to etoposide treatment.
  • Moreover, a significant negative correlation between NFKB1 and TAL1 or LMO1 was found in primary human TAL1/LMO1 double-positive T-ALL samples previously described by Ferrando et al. Thus, TAL1 modulates NFKB1 expression and an NF-kappaB-dependent transcriptional program in a subset of human T-cell leukemia cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778171.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899; United States / NCI NIH HHS / CA / R01-CA077474; United States / NCI NIH HHS / CA / R01-CA081065
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NF-kappa B p50 Subunit; 0 / NFKB1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Transcription Factor RelA; 135471-20-4 / TAL1 protein, human; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


62. Schelonka RL, Ivanov II, Vale AM, Szymanska E, Zemlin M, Gartland GL, Schroeder HW Jr: The CDR-H3 repertoire from TdT-deficient adult bone marrow is a close, but not exact, homologue of the CDR-H3 repertoire from perinatal liver. J Immunol; 2010 Nov 15;185(10):6075-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V(H)7183-containing VDJCμ transcripts from these cells were amplified, cloned, sequenced, and compared with transcripts from wild-type perinatal liver and adult BM.
  • What minor differences were detected in the pro-B cell stage tended to diminish with B cell maturation, suggesting strong environmental or Ag-driven pressure to achieve a specific range of V(H)DJ(H) usage regardless of the extent of N nucleotide addition.
  • However, although the patterns of V(H)DJ(H) usage in the TdT-deficient B lineage cells paralleled that of wild-type adult cells, the length distribution, global amino acid composition, and charge distribution of the CDR-H3 repertoire proved to be a close, although not exact, homologue of the CDR-H3 repertoire first expressed by late pre-B cells in the TdT-insufficient perinatal liver.
  • Thus, although differing in V(H) content, TdT-deficient mice appear to represent a good, although not perfect, model for testing the role of perinatal CDR-H3 limitations on late B cell development and Ab responses.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2000 Jan;94(1):24-32 [10607487.001]
  • [Cites] Immunogenetics. 2010 Oct;62(10):653-66 [20714894.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):257-63 [11418657.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3486-93 [11544342.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):440-4 [12540919.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):444-8 [12540920.001]
  • [Cites] Clin Immunol. 2003 Jun;107(3):186-97 [12804532.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4624-9 [15034081.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):4118-22 [6287467.001]
  • [Cites] Nature. 1983 Apr 14;302(5909):575-81 [6300689.001]
  • [Cites] Annu Rev Biochem. 1984;53:595-623 [6383201.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):727-33 [6092962.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):752-5 [6092963.001]
  • [Cites] J Exp Med. 1990 Jan 1;171(1):265-92 [2104919.001]
  • [Cites] EMBO J. 1990 Jul;9(7):2133-40 [2113468.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4343-50 [1753104.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):222-9 [1607655.001]
  • [Cites] EMBO J. 1993 May;12(5):1819-26 [8491175.001]
  • [Cites] Science. 1993 Aug 27;261(5125):1171-5 [8356451.001]
  • [Cites] Mol Immunol. 1994 Feb;31(3):169-217 [8114766.001]
  • [Cites] J Immunol. 1996 Mar 15;156(6):2077-84 [8690895.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):600-3 [8698848.001]
  • [Cites] Immunol Rev. 1995 Dec;148:201-19 [8825288.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):1-8 [8980108.001]
  • [Cites] J Mol Biol. 1998 Jul 3;280(1):1-9 [9653027.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):7023-30 [9862739.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):188-97 [10428499.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7773-80 [15944280.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6624-32 [16272317.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):293-301 [16429139.001]
  • [Cites] J Exp Med. 2006 Jun 12;203(6):1567-78 [16754718.001]
  • [Cites] Eur J Immunol. 2007 Apr;37(4):1010-21 [17345580.001]
  • [Cites] J Virol. 2007 Sep;81(17):9331-8 [17567700.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8416-24 [19050259.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):851-8 [20018621.001]
  • [Cites] Immunity. 2000 Jul;13(1):37-45 [10933393.001]
  • (PMID = 20956348.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ HM154548/ HM154549/ HM154550/ HM154551/ HM154552/ HM154553/ HM154554/ HM154555/ HM154556/ HM154557/ HM154558/ HM154559/ HM154560/ HM154561/ HM154562/ HM154563/ HM154564/ HM154565/ HM154566/ HM154567/ HM154568/ HM154569/ HM154570/ HM154571/ HM154572/ HM154573/ HM154574/ HM154575/ HM154576/ HM154577/ HM154578/ HM154579/ HM154580/ HM154581/ HM154582/ HM154583/ HM154584/ HM154585/ HM154586/ HM154587/ HM154588/ HM154589/ HM154590/ HM154591/ HM154592/ HM154593/ HM154594/ HM154595/ HM154596/ HM154597/ HM154598/ HM154599/ HM154600/ HM154601/ HM154602/ HM154603/ HM154604/ HM154605/ HM154606/ HM154607/ HM154608/ HM154609/ HM154610/ HM154611/ HM154612/ HM154613/ HM154614/ HM154615/ HM154616/ HM154617/ HM154618/ HM154619/ HM154620/ HM154621/ HM154622/ HM154623/ HM154624/ HM154625/ HM154626/ HM154627/ HM154628/ HM154629/ HM154630/ HM154631/ HM154632/ HM154633/ HM154634/ HM154635/ HM154636/ HM154637/ HM154638/ HM154639/ HM154640/ HM154641/ HM154642/ HM154643/ HM154644/ HM154645/ HM154646/ HM154647/ HM154648/ HM154649/ HM154650/ HM154651/ HM154652/ HM154653/ HM154654/ HM154655/ HM154656/ HM154657/ HM154658/ HM154659/ HM154660/ HM154661/ HM154662/ HM154663/ HM154664/ HM154665/ HM154666/ HM154667/ HM154668/ HM154669/ HM154670/ HM154671/ HM154672/ HM154673/ HM154674/ HM154675/ HM154676/ HM154677/ HM154678/ HM154679/ HM154680/ HM154681/ HM154682/ HM154683/ HM154684/ HM154685/ HM154686/ HM154687/ HM154688/ HM154689/ HM154690/ HM154691/ HM154692/ HM154693/ HM154694/ HM154695/ HM154696/ HM154697/ HM154698/ HM154699/ HM154700/ HM154701/ HM154702/ HM154703/ HM154704/ HM154705/ HM154706/ HM154707/ HM154708/ HM154709/ HM154710/ HM154711/ HM154712/ HM154713/ HM154714/ HM154715/ HM154716/ HM154717/ HM154718/ HM154719/ HM154720/ HM154721/ HM154722/ HM154723/ HM154724/ HM154725/ HM154726/ HM154727/ HM154728/ HM154729/ HM154730/ HM154731/ HM154732/ HM154733/ HM154734/ HM154735/ HM154736/ HM154737/ HM154738/ HM154739/ HM154740/ HM154741/ HM154742/ HM154743/ HM154744/ HM154745/ HM154746/ HM154747/ HM154748/ HM154749/ HM154750/ HM154751/ HM154752/ HM154753/ HM154754/ HM154755/ HM154756/ HM154757/ HM154758/ HM154759/ HM154760/ HM154761/ HM154762/ HM154763/ HM154764/ HM154765/ HM154766/ HM154767/ HM154768/ HM154769/ HM154770/ HM154771/ HM154772/ HM154773/ HM154774/ HM154775/ HM154776/ HM154777/ HM154778/ HM154779/ HM154780/ HM154781/ HM154782/ HM154783/ HM154784/ HM154785/ HM154786/ HM154787/ HM154788/ HM154789/ HM154790/ HM154791/ HM154792/ HM154793/ HM154794/ HM154795/ HM154796/ HM154797/ HM154798/ HM154799/ HM154800/ HM154801/ HM154802/ HM154803/ HM154804/ HM154805/ HM154806/ HM154807/ HM154808/ HM154809/ HM154810/ HM154811/ HM154812/ HM154813/ HM154814/ HM154815/ HM154816/ HM154817/ HM154818/ HM154819/ HM154820/ HM154821/ HM154822/ HM154823/ HM154824/ HM154825/ HM154826/ HM154827/ HM154828/ HM154829/ HM154830/ HM154831/ HM154832/ HM154833/ HM154834/ HM154835/ HM154836/ HM154837/ HM154838/ HM154839/ HM154840/ HM154841/ HM154842/ HM154843/ HM154844/ HM154845/ HM154846/ HM154847/ HM154848/ HM154849/ HM154850/ HM154851/ HM154852/ HM154853/ HM154854/ HM154855/ HM154856/ HM154857/ HM154858/ HM154859/ HM154860/ HM154861/ HM154862/ HM154863/ HM154864/ HM154865/ HM154866/ HM154867/ HM154868/ HM154869/ HM154870/ HM154871/ HM154872/ HM154873/ HM154874/ HM154875/ HM154876/ HM154877/ HM154878/ HM154879/ HM154880/ HM154881/ HM154882/ HM154883/ HM154884/ HM154885/ HM154886/ HM154887/ HM154888/ HM154889/ HM154890/ HM154891/ HM154892/ HM154893/ HM154894/ HM154895/ HM154896/ HM154897/ HM154898/ HM154899/ HM154900/ HM154901/ HM154902/ HM154903/ HM154904/ HM154905/ HM154906/ HM154907/ HM154908/ HM154909/ HM154910/ HM154911/ HM154912/ HM154913/ HM154914/ HM154915/ HM154916/ HM154917/ HM154918/ HM154919/ HM154920/ HM154921/ HM154922/ HM154923/ HM154924/ HM154925/ HM154926/ HM154927/ HM154928/ HM154929/ HM154930/ HM154931/ HM154932/ HM154933/ HM154934/ HM154935/ HM154936
  • [Grant] United States / NIAID NIH HHS / AI / AI007051; United States / NIAID NIH HHS / AI / T32 AI007051; United States / NIAID NIH HHS / AI / AI048115; United States / NIAID NIH HHS / AI / AI078449; United States / NIAID NIH HHS / AI / R56 AI048115; United States / NIAID NIH HHS / AI / R21 AI078449; United States / NIAID NIH HHS / AI / R01 AI048115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  • [Other-IDs] NLM/ NIHMS469908; NLM/ PMC3670101
  •  go-up   go-down


63. Gündüz E, Demirel G, Bal C, Gulbas Z: Evaluation of mobilized peripheral stem cells according to CD34 and aldehyde dehydrogenase expression and effect of SSC(lo) ALDH(br) cells on hematopoietic recovery. Cytotherapy; 2010 Dec;12(8):1006-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty patients (20 males and 10 females), who were candidates for autologous peripheral blood stem cell transplantation, were included in the study.
  • Primary diagnoses were multiple myeloma (n = 14), Hodgkin's lymphoma (n = 7), non-Hodgkin's lymphoma (n = 2), acute myloid leukemia (n = 2), chronic lymphocytic leukemia (n = 1) and germ cell testis tumor (n = 1).
  • We could not find a relationship between the transplanted SSC(lo) CD45(dim) CD34(hi) cell dose or SSC(lo) ALDH(br) cell dose and platelet or neutrophil recovery.
  • CONCLUSIONS: According to our data, numbers of SSC(lo) ALDH(br) cells are in very good agreement with numbers of SSC(lo) CD45(dim) CD34(hi) cells and can be a predictor of stem cell mobilization.
  • [MeSH-major] Graft Survival / immunology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Leukemia / therapy. Lymphoma / therapy
  • [MeSH-minor] Adult. Aldehyde Dehydrogenase / metabolism. Antigens, CD34 / metabolism. Blood Component Removal. Cells, Cultured. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoiesis / drug effects. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735165.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


64. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL: Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail; 2006 Oct;12(8):635-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction.
  • BACKGROUND: Cardiotrophin-1 (CT-1) is an important inflammatory cytokine; its presence has been documented in patients after acute myocardial infarction (AMI).
  • We sought to investigate this and compared it with N terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of death or heart failure.

  • Genetic Alliance. consumer health - Myocardial infarction 1.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Card Fail. 2006 Oct;12(8):641-3 [17045184.001]
  • (PMID = 17045183.001).
  • [ISSN] 1532-8414
  • [Journal-full-title] Journal of cardiac failure
  • [ISO-abbreviation] J. Card. Fail.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Peptide Fragments; 0 / cardiotrophin 1; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


65. Mansson R, Zandi S, Welinder E, Tsapogas P, Sakaguchi N, Bryder D, Sigvardsson M: Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity. Blood; 2010 Apr 1;115(13):2601-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity.
  • This allowed us to subfractionate common lymphoid progenitors and pre-pro-B (fraction A) cells into lambda5(-)Rag1(low), lambda5(-)Rag1(high), and lambda5(+)Rag1(high) cells.
  • Rag1(high) cells displayed reduced NK-cell potential with preserved capacity to generate B- and T-lineage cells, whereas the lambda5(+) cells were B-lineage restricted.
  • These data suggest that the classic common lymphoid progenitor compartment composes a mixture of cells with relatively restricted lineage potentials, thus opening new possibilities to investigate early hematopoiesis.
  • [MeSH-minor] Animals. Antigens, Ly / biosynthesis. Antigens, Ly / genetics. B-Cell-Specific Activator Protein / biosynthesis. B-Cell-Specific Activator Protein / genetics. Biomarkers. Cell Lineage. Cells, Cultured / cytology. Cells, Cultured / metabolism. Coculture Techniques. Flow Cytometry. GPI-Linked Proteins. Gene Expression Profiling. Gene Knock-In Techniques. Genes, Reporter. Homeodomain Proteins / genetics. Killer Cells, Natural / cytology. Lymphocyte Subsets / cytology. Lymphopoiesis. Mice. Mice, Transgenic. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / biosynthesis. Trans-Activators / genetics


66. Mowatt L, Matthews T, Anderson I: Sustained visual recovery after treatment with intrathecal methotrexate in a case of optic neuropathy caused by chronic lymphocytic leukemia. J Neuroophthalmol; 2005 Jun;25(2):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained visual recovery after treatment with intrathecal methotrexate in a case of optic neuropathy caused by chronic lymphocytic leukemia.
  • A 68-year-old woman with chronic lymphocytic leukemia (CLL) had acute optic neuropathy associated with cerebrospinal fluid evidence of meningeal spread of CLL.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Methotrexate / therapeutic use. Optic Nerve Neoplasms / drug therapy. Visual Acuity / physiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937434.001).
  • [ISSN] 1070-8022
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


67. Hu WB, Gao QP, Chen YH: [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):404-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation].
  • To investigate the effect of bone marrow mesenchymal stem cells (BMMSC) on acute graft versus host disease (aGVHD) and graft versus leukemia (GVL) after allogeneic bone marrow transplantation (allo-BMT), both bone marrow cells and BMMSC obtained after three to four weeks of culture from donor mice were transplanted into the recipient mice injected with acute lymphocytic leukemia cells 5 days before, the control group was injected with bone marrow cells alone.
  • The survial time after allo-BMT was recorded; the general manifestation and pathological changes of aGVHD in recipient mice were observed; the effects of BMMSC on the quatity of CD4(+) and CD8(+) T cell in vivo after allo-BMT were evaluated by flow cytometry; chimerism was detected by sex chromosome.
  • The results showed BMMSC could increase obviously the survival time, and delay onset of aGVHD, BMMSC could decrease the amount of CD4(+) T cell and increase CD8(+) T cell in vivo.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972130.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Salmon JM, Slater NJ, Hall MA, McCormack MP, Nutt SL, Jane SM, Curtis DJ: Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene. Blood; 2007 Nov 15;110(10):3573-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene.
  • The stem cell leukemia (SCL) gene encodes a basic helix-loop-helix transcription factor expressed in erythroid, megakaryocyte, and mast-cell lineages.
  • SCL(-/Delta) mice had markedly increased numbers of mast-cell progenitors (MCPs) within the peritoneal fluid, bone marrow, and spleen.
  • Fractionation of bone marrow myeloid progenitors demonstrated that these MCPs were present in the megakaryocyte-erythroid-restricted cell fraction.
  • In contrast, unilineage MCPs from control mice were present in the cell fraction with granulocyte-macrophage potential.
  • The aberrant mast-cell differentiation of SCL(-/Delta) megakaryocyte-erythroid progenitors was associated with increased expression of GATA-2.
  • Despite increased numbers of MCPs in SCL(-/Delta) mice, numbers of mature tissue mast cells were not increased unless SCL(-/Delta) mice were treated with IL-3 and stem-cell factor.
  • In part, this may be due to a requirement for SCL in normal mast-cell maturation: SCL(-/Delta) mast cells had reduced expression of the high-affinity IgE receptor and mast cell proteases, MCP-5 and MCP-6.
  • Together, these studies suggest that loss of SCL leads to aberrant mast-cell differentiation of megakaryocyte-erythroid progenitors.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Differentiation / genetics. Mast Cells / cytology. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Cell Count. Cells, Cultured. Erythroid Cells / cytology. GATA2 Transcription Factor / genetics. Humans. Leukemia / genetics. Macrophages / cytology. Megakaryocytes / cytology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Stem Cells / cytology. Transfection. Up-Regulation


69. Manosroi A, Khositsuntiwong N, Götz F, Werner RG, Manosroi J: Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res; 2009;19(2):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles.
  • Transdermal absorption of luciferase plasmid (pLuc) was enhanced by loading in elastic cationic liposomes and niosomes and the application of iontophoresis or the stratum corneum (SC) stripping method.
  • Cationic liposomes (DPPC/Chol/DDAB at a 1:1:1 molar ratio) and niosomes (Tween61/Chol/DDAB at a 1:1:0.5 molar ratio) were prepared by the freeze-dried empty liposomes method.
  • The elastic vesicles were prepared by hydrating the lipid or surfactant film by 25% of ethanol instead of distilled water.
  • Gel electrophoresis of all nanovesicles showed the 100% pLuc entrapment efficiency.
  • All nanovesicles loaded with pLuc showed larger vesicular sizes than the nonloaded vesicles of about 1.4 times for liposomes and 1.7 times for niosomes.
  • The nanovesicles loaded with pLuc demonstrated less positive zeta potential than the nonloaded vesicles.
  • The pLuc loaded in elastic vesicles kept at 4 +/- 2 and 27 +/- 2 degrees C for 8 weeks gave the remaining pLuc of about 70 and 60% for liposomes and 85 and 73% for niosomes, respectively.
  • For nonelastic vesicles kept at 4 +/- 2 degrees C, 56 and 61% of the remaining pLuc were observed for liposomes and niosomes, respectively, while at 27 +/- 2 degrees C, all pLuc were degraded.
  • The deformability indices of the elastic liposomes and niosomes loaded with the pLuc were 16.64 +/- 2.92 and 20.72 +/- 0.82, whereas the nonelastic vesicles gave 9.35 +/- 0.09 and 10.08 +/- 0.12, respectively.
  • Transdermal absorption through rat skin pretreated with SC stripping or treated with iontophoresis of pLuc loaded in nanovesicles by vertical Franz diffusion cells was investigated at 37 degrees C.
  • The cells were stopped and the skin and the receiving solution were withdrawn at 1, 3, and 6 hours and the pLuc contents in the stripped SC, whole skin (viable epidermis and dermis; VED), and the receiving solution were assayed by the modified gel electrophoresis and gel documentation.
  • Without the SC stripping technique or iontophoresis, the pLuc loaded and nonloaded in nonelastic cationic liposomes or niosomes were not found in SC, VED, and receiving solution.
  • The fluxes in the whole skin of pLuc loaded in nonelastic liposomes and niosomes with SC stripping and iontophoresis at 6 hours gave 2.73 +/- 0.46 and 3.83 +/- 0.73, and 7.01 +/- 1.22 and 9.60 +/- 1.31 g/cm(2)/h, respectively, while pLuc loaded in elastic liposomes and niosomes without the SC stripping and iontophoresis at 6 hours showed 2.79 +/- 0.09 and 2.84 +/- 0.04 g/cm(2)/h, respectively.
  • The pLuc loaded in elastic niosomes or in nonelastic niosomes with iontophoresis was found in the receiving solution with a higher amount than that loaded in elastic liposomes or nonelastic liposomes with iontophoresis.
  • The fluxes in the receiving solution of pLuc loaded in nonelastic liposomes and niosomes with iontophoresis at 6 hours were 6.71 +/- 0.31 and 8.82 +/- 0.28 g/cm(2)/h, respectively.
  • For elastic liposomes and niosomes, the fluxes of the loaded pLuc in the receiving solution were the same, at about 1.9 g/cm(2)/h.
  • Although pLuc loaded in nonelastic niosomes with iontophoresis gave the highest delivery of the plasmid in VED and receiving solution, a more promising applicable approach for gene delivery has been suggested to be the elastic niosomal systems, since no equipment is required.
  • [MeSH-major] Plasmids / metabolism. Skin / metabolism
  • [MeSH-minor] Administration, Cutaneous. Animals. Cations / metabolism. DNA / metabolism. Freeze Drying. Liposomes / metabolism. Luciferases / metabolism. Male. Quaternary Ammonium Compounds. Rats. Rats, Sprague-Dawley. Surface-Active Agents / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241277.001).
  • [ISSN] 1532-2394
  • [Journal-full-title] Journal of liposome research
  • [ISO-abbreviation] J Liposome Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cations; 0 / Liposomes; 0 / Quaternary Ammonium Compounds; 0 / Surface-Active Agents; 13146-86-6 / didodecyldimethylammonium; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


70. Wu M, Sun XF, Xu ZM, Zhang XY, Li FR, Wang XG, Chen XL, Lin HQ, Wen HG, Sun X, Song TW: [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug;13(4):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
  • To test the European BIOMED-1 Concerted Action proposed technique to detect minimal residual disease (MRD) in the chinese patients with precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) by triple-staining flow cytometry and to define both normal and aberrant phenotypic profiles of precursor B cells, a series of bone marrow samples, 35 from precursor-B-ALL (13 in newly diagnosed cases, 15 at the end of remission induction therapy and 7 at end of the consolidations), and 19 from normal controls, were immunophenotyped with the five triple-staining antibodies (TdT/CD10/CD19, CD10/CD20/CD19, CD34/CD38/CD19, CD34/CD22/CD19 and CD19/CD34/CD45) recom-mended by the BIOMED-1 using common flow cytometric protocols.
  • The results showed that three major CD19(+) cell subpopulations were identified in the normal controls, representing three consecutive maturation stages.
  • The subpopulations in the precursor-B-ALL cases disappeared and were replaced with a great number of luekemic cells which had different characteristics of phenotypes, and then they reappeared with almost same characteristics as the normal CD19(+) cells after the patients achieved complete remission.
  • When the five triple-staining antibody combinations were used, the phenotypic aberrancies could be identified in 12/13 (92.3%) cases with newly diagnosed precursor-B-ALL, at least one triple-labeling per case at the level of 0.01% or more.
  • At the end of remission induction, the phenotypic aberrancies could be detected in 5/15 (33.3%), of which, 3/8 (37.5%) cases with the leukemic phenotypes detected both at the newly diagnosis and at the end of induction.
  • It is concluded that the flow cytometric detection of precursor-B-ALL-MRD proposed by BIOMED-1 Concerted Action were well realized in this study.
  • The one precursor-B-ALL cell can be effectively detected out of 10(4) normal bone marrow cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129033.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


71. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM: Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene; 2005 Aug 11;24(34):5396-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
  • The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis.
  • Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia.
  • Less is known concerning acute leukemia.
  • One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis.
  • We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation.
  • As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines.
  • We then directly addressed the role played by both isoforms in this type of leukemia.
  • Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007226.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-01A3; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-01A3
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / RNA, Small Interfering; 0 / WNT16 protein, human; 0 / Wnt Proteins
  •  go-up   go-down


72. Campino S, Forton J, Auburn S, Fry A, Diakite M, Richardson A, Hull J, Jallow M, Sisay-Joof F, Pinder M, Molyneux ME, Taylor TE, Rockett K, Clark TG, Kwiatkowski DP: TLR9 polymorphisms in African populations: no association with severe malaria, but evidence of cis-variants acting on gene expression. Malar J; 2009 Mar 13;8:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, an association study of four common single nucleotide polymorphisms was performed on both family- and population-based studies from Malawian and Gambian populations (n>6000 individual).
  • For this work, an allele specific expression (ASE) assay on a panel of HapMap cell lines was carried out.
  • Using an allele specific expression assay it was observed that TLR9 expression is affected by cis-acting variants, these results were replicated in a second experiment using biological replicates.
  • This analysis considered all common variants in the region, but it is remains possible that there are rare variants with association signals.

  • Genetic Alliance. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jun 1;101(11):4500-4 [12560217.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e99 [17571926.001]
  • [Cites] Genet Epidemiol. 2004 Apr;26(3):186-205 [15022206.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):394-9 [15052269.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4926-33 [15067072.001]
  • [Cites] Nature. 2004 Aug 12;430(7001):743-7 [15269782.001]
  • [Cites] Science. 2004 Oct 22;306(5696):647-50 [15499010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):506-16 [8447318.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1399-404 [7723795.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):19-25 [15630134.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1217-24 [17873874.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1208-16 [17873875.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2496-503 [18250459.001]
  • [Cites] J Infect Dis. 2008 Sep 1;198(5):772-80 [18662133.001]
  • [Cites] Hum Hered. 2009;67(1):26-37 [18931507.001]
  • [Cites] PLoS One. 2008;3(12):e4105 [19116668.001]
  • [Cites] Anal Biochem. 2005 Apr 15;339(2):231-41 [15797563.001]
  • [Cites] Environ Microbiol. 2005 Jul;7(7):1024-8 [15946299.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1365-9 [16251966.001]
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3963-71 [16301213.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e78 [16362079.001]
  • [Cites] J Infect Dis. 2006 Jul 15;194(2):184-8 [16779724.001]
  • [Cites] Am J Hum Genet. 2006 Sep;79(3):539-43 [16909391.001]
  • [Cites] Genome Res. 2007 Jan;17(1):82-7 [17135570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1919-24 [17261807.001]
  • [Cites] J Commun Dis. 2006 Mar;38(3):230-45 [17373355.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):548-59 [17600128.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • (PMID = 19284650.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600230; United Kingdom / Medical Research Council / / G19/9; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toll-Like Receptor 9
  • [Other-IDs] NLM/ PMC2660361
  •  go-up   go-down


73. Takamori M, Motomura M, Fukudome T, Yoshikawa H: Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol; 2007 Nov;14(11):1230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lambert-Eaton myasthenic syndrome (LEMS), often associated with small-cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals.
  • In most patients, it is caused by autoantibodies against the P/Q-type voltage-gated calcium channels (VGCC) that trigger ACh release.
  • The M1-type pre-synaptic muscarinic ACh receptor (M1 mAChR) modulates cholinergic neuromuscular transmission by linking to P/Q-type VGCC, and may partially compensate for the reduced calcium entry.
  • (b) all five anti-VGCC-negative LEMS patients, one of whose serum had previously passively transferred LEMS-type electrophysiological defects to mice;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764462.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Receptor, Muscarinic M1
  •  go-up   go-down


74. Yang CY, Chen CC, Chen CY, Kuo HW: Air pollution and hospital admissions for asthma in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A; 2007 Jan 15;70(2):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Air pollution and hospital admissions for asthma in a subtropical city: Taipei, Taiwan.
  • This study was undertaken to determine whether there is an association between exposure to air pollutants levels and number of hospital admissions for asthma in Taipei, Taiwan.
  • Hospital admissions for asthma and ambient air pollution data for Taipei were obtained for the period from 1996 through 2003.
  • The relative risk of hospital admission for asthma was estimated using a case-crossover approach, controlling for weather variables, day of the week, seasonality, and long-term time trends.
  • In the single-air-pollutant model, on warm days (> or = 25 degrees C) statistically significant positive associations were found for SO2, NO2, and CO levels with an increase in asthmatic admissions.
  • On cool days (< 25 degrees C), all air pollutants were significantly associated with elevated asthma admissions except SO2.
  • For the two-air-pollutant model, CO significantly increases hospital admissions for asthma in combination with each of the other four pollutants on warm days.
  • On cool days, NO2 and O3 significantly elevated asthma rates in all the two-air-pollutant models.
  • This study provides evidence that higher levels of ambient air pollutant concentrations increase the risk of hospital admissions for asthma.
  • [MeSH-major] Air Pollutants / toxicity. Air Pollution / adverse effects. Asthma / epidemiology. Hospitalization / statistics & numerical data
  • [MeSH-minor] Carbon Monoxide / analysis. Carbon Monoxide / toxicity. Cities. Environmental Monitoring. Epidemiological Monitoring. Humans. Nitrogen Dioxide / analysis. Nitrogen Dioxide / toxicity. Ozone / analysis. Ozone / toxicity. Particulate Matter / analysis. Particulate Matter / toxicity. Sulfur Dioxide / analysis. Taiwan. Tropical Climate

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Air Pollution.
  • MedlinePlus Health Information. consumer health - Asthma.
  • Hazardous Substances Data Bank. OZONE .
  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • Hazardous Substances Data Bank. Carbon monoxide .
  • Hazardous Substances Data Bank. Sulfur dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365571.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Particulate Matter; 0UZA3422Q4 / Sulfur Dioxide; 66H7ZZK23N / Ozone; 7U1EE4V452 / Carbon Monoxide; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


75. Lausen J, Pless O, Leonard F, Kuvardina ON, Koch B, Leutz A: Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1. J Biol Chem; 2010 Feb 19;285(8):5338-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Erythrocytes / metabolism. Erythroid Precursor Cells / metabolism. Erythropoiesis / physiology. Gene Expression Regulation, Enzymologic / physiology. Proto-Oncogene Proteins / metabolism. Ubiquitin-Conjugating Enzymes / biosynthesis
  • [MeSH-minor] Antigens, CD34. Cell Differentiation / physiology. Humans. K562 Cells. Ubiquitin / genetics. Ubiquitin / metabolism. Ubiquitination / physiology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] Blood. 1996 Jan 1;87(1):102-11 [8547631.001]
  • [Cites] FEBS Lett. 1995 Dec 18;377(2):193-6 [8543049.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4123-9 [8861941.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):473-9 [9472016.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7030-7 [9507011.001]
  • [Cites] Development. 1999 Oct;126(20):4603-15 [10498694.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):588-95 [15558010.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Mol Cell Proteomics. 2004 May;3(5):501-9 [14963112.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Vox Sang. 2004 Jul;87 Suppl1:15-9 [15200597.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • [Cites] Science. 1982 Feb 19;215(4535):978-80 [7156977.001]
  • [Cites] Gene. 1985;35(3):321-31 [3899863.001]
  • [Cites] Blood. 1988 Apr;71(4):1153-6 [2833326.001]
  • [Cites] Adv Exp Med Biol. 1991;307:191-205 [1666814.001]
  • [Cites] Biotechnology (N Y). 1993 Oct;11(10):1138-43 [7764094.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1200-8 [8118024.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8797-802 [8132613.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Blood. 1995 Feb 1;85(3):675-84 [7833471.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9507-16 [7721879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4982-6 [7761435.001]
  • [Cites] Blood. 1995 Jul 15;86(2):666-76 [7605997.001]
  • [Cites] Curr Biol. 1995 Aug 1;5(8):909-22 [7583149.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12956-66 [15677454.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6355-62 [16024775.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):369-81 [16633365.001]
  • [Cites] Dev Biol. 2006 Jun 15;294(2):525-40 [16626682.001]
  • [Cites] Blood. 2006 Aug 1;108(3):986-92 [16621969.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1511-8 [16926849.001]
  • [Cites] J Mol Cell Cardiol. 2006 Oct;41(4):567-79 [16949602.001]
  • [Cites] Biochem J. 2006 Oct 15;399(2):297-304 [16800816.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2998-3004 [16849639.001]
  • [Cites] Blood Cells Mol Dis. 2006 Nov-Dec;37(3):210-7 [16978890.001]
  • [Cites] Physiol Genomics. 2006 Dec 13;28(1):114-28 [16940433.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2704-7 [17616641.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3005-14 [18184866.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1658-62 [18436863.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1056-67 [18550854.001]
  • [Cites] Nucleic Acids Res. 2008 Sep;36(16):5221-31 [18684996.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D755-61 [18996895.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2191-201 [19011221.001]
  • [Cites] Nat Biotechnol. 2009 Mar;27(3):264-74 [19234449.001]
  • [Cites] Blood. 2009 May 28;113(22):5456-65 [19346495.001]
  • [Cites] Exp Hematol. 2009 Oct;37(10):1143-1156.e3 [19607874.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1193-207 [10582347.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2248-59 [10688671.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6792-803 [11118214.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):57-64 [11262875.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):373-428 [11917093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18365-72 [11904294.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Exp Hematol. 2002 Jul;30(7):634-9 [12135659.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1048-57 [12773487.001]
  • [Cites] Nat Immunol. 2003 Jul;4(7):607-15 [12830135.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Trends Cardiovasc Med. 2003 Aug;13(6):254-9 [12922023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11842-9 [14504387.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):11-24 [14725896.001]
  • (PMID = 20028976.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Ubiquitin; 135471-20-4 / TAL1 protein, human; EC 6.3.2.19 / UBE2H protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  • [Other-IDs] NLM/ PMC2820762
  •  go-up   go-down


76. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W: Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One; 2010 Dec 28;5(12):e15262
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.
  • Recent data suggests that Hh signaling plays a role in normal B-cell development, and we hypothesized that Hh signaling may be important in precursor B-cell acute lymphocytic leukemia (B-ALL).
  • We found that the expression of Hh pathway components was common in human B-ALL cell lines and clinical samples.
  • These data demonstrate that Hh pathway activation is common in B-ALL and represents a novel therapeutic target regulating self-renewal and persistence of the malignant clone.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23 [10430905.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1814-23 [17536012.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] J Biol Chem. 2007 Dec 28;282(52):37370-7 [17895245.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):238-49 [18772113.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6646-9 [18842035.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2383-6 [19052992.001]
  • [Cites] Genes Dev. 2009 Jan 1;23(1):24-36 [19136624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):776-9 [19169242.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Blood. 2009 Jul 30;114(5):995-1004 [19483124.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6007-10 [19638582.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Anticancer Res. 2009 Nov;29(11):4629-32 [20032413.001]
  • [Cites] EMBO Mol Med. 2009 Sep;1(6-7):338-51 [20049737.001]
  • [Cites] Leukemia. 2010 May;24(5):1025-36 [20200556.001]
  • [Cites] Clin Cancer Res. 2010 Jun 15;16(12):3130-40 [20530699.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Cell. 1996 Nov 15;87(4):661-73 [8929535.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):975-85 [16293577.001]
  • (PMID = 21203400.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075826; United States / NCI NIH HHS / CA / P01 CA015396; United States / NCI NIH HHS / CA / R01 CA127574; United States / NCI NIH HHS / CA / R01CA127574; United States / NCI NIH HHS / CA / R01 CA127574-05; United States / NHLBI NIH HHS / HL / HL83077; United States / NHLBI NIH HHS / HL / HL75826; United States / NHLBI NIH HHS / HL / R01 HL083077; United States / NHLBI NIH HHS / HL / T32 HL086345; United States / NCI NIH HHS / CA / P01CA15396
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / IPI-926; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / Veratrum Alkaloids; EC 1.2.1.3 / Aldehyde Dehydrogenase; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3011010
  •  go-up   go-down


77. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%.


78. Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, Matsunaga T, Inukai T, Goto H, Altura RA, Sugita K, Arisaka O, Look AT, Inaba T: Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. J Biol Chem; 2010 Jan 15;285(3):1850-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.
  • The E2A-HLF fusion transcription factor generated by t(17;19)(q22;p13) translocation is found in a small subset of pro-B cell acute lymphoblastic leukemias (ALLs) and promotes leukemogenesis by substituting for the antiapoptotic function of cytokines.
  • Forced expression of E2A-HLF in t(17;19)(-) leukemia cells up-regulated Survivin expression, suggesting that Survivin is a downstream target of E2A-HLF.
  • Analysis using a counterflow centrifugal elutriator revealed that t(17;19)+ ALL cells express Survivin throughout the cell cycle.
  • Reporter assays revealed that E2A-HLF induces survivin expression at the transcriptional level likely through indirect down-regulation of a cell cycle-dependent cis element in the promoter region.
  • Down-regulation of Survivin function by a dominant negative mutant of Survivin or reduction of Survivin expression induced massive apoptosis throughout the cell cycle in t(17;19)+ cells mainly through caspase-independent pathways involving translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus.
  • These data indicated that reversal of AIF translocation by Survivin, which is induced by E2A-HLF throughout the cell cycle, is one of the key mechanisms in the protection of t(17;19)+ leukemia cells from apoptosis.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Basic-Leucine Zipper Transcription Factors / metabolism. Microtubule-Associated Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Recombinant Fusion Proteins / metabolism. Translocation, Genetic / genetics. Up-Regulation
  • [MeSH-minor] Animals. Apoptosis. Base Sequence. Caspases / metabolism. Cell Cycle / genetics. Cell Line, Tumor. Cell Survival / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Humans. Inhibitor of Apoptosis Proteins. Mice. Molecular Sequence Data. Mutation. Precursor Cells, B-Lymphoid / cytology. Precursor Cells, B-Lymphoid / metabolism. Promoter Regions, Genetic / genetics. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Oct;2(4):279-88 [12398892.001]
  • [Cites] J Cell Biochem. 2008 Oct 1;105(2):381-90 [18553460.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):401-6 [12590264.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4266-80 [12833149.001]
  • [Cites] J Cell Physiol. 2003 Oct;197(1):8-29 [12942537.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4179-86 [12920030.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):39-48 [14712209.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3185-91 [15070701.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Science. 1992 Jul 24;257(5069):531-4 [1386162.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1608-20 [1516826.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3403-13 [8164688.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):266-75 [7835337.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1211-24 [8608207.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):541-4 [8700228.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):545-7 [8700229.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2609-14 [9122243.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:305-11 [10567210.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 17;93(20):1541-52 [11604477.001]
  • [Cites] Science. 2002 Jul 12;297(5579):259-63 [12114629.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3980-90 [9166836.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):6035-43 [9742120.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Blood. 1999 Jan 1;93(1):321-32 [9864177.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1457-62 [9990045.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2754-62 [10082541.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):309-19 [10518212.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):343-52 [10518215.001]
  • [Cites] Neoplasma. 2006;53(3):206-12 [16652189.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):264-72 [16621561.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):476-86 [16557517.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2247-56 [16728972.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4844-62 [17470554.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2439-47 [17600109.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] Tohoku J Exp Med. 2008 Sep;216(1):25-34 [18719335.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 19887369.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Basic-Leucine Zipper Transcription Factors; 0 / HLF protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Recombinant Fusion Proteins; 0 / TCF3 protein, human; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2804343
  •  go-up   go-down


79. Chutiwitoonchai N, Shen Y, Zheng H, Xiong H, Zhao G, Imtawil K, Intapan PM, Wongkham S, Wongkham C: Opisthorchis viverrini: Gene expression profiling of carcinogenic adult liver fluke worms using 5' SAGE. Exp Parasitol; 2008 Dec;120(4):306-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most abundant tag sequences were vitelline B precursor protein and myoglobin.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786530.001).
  • [ISSN] 1090-2449
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther; 2006 Sep;5(9):2378-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple tumor cell lines of varying histiotypes, including A549 (lung adenocarcinoma), 786-O (renal cell carcinoma), HeLa (cervical carcinoma), MDA-MB-231 (breast), K562 (chronic myelogenous leukemia), Jurkat (acute T-cell leukemia), MEC-2 (B-chronic lymphocytic leukemia), and U251 and D37 (glioma), as well as cells derived from primary human glioma tumors that are likely a more clinically relevant model were treated with sorafenib or bortezomib alone or in combination.
  • Sorafenib and bortezomib synergistically induced a marked increase in mitochondrial injury and apoptosis, reflected by cytochrome c release, caspase-3 cleavage, and poly(ADP-ribose) polymerase degradation in a broad range of solid tumor and leukemia cell lines.
  • These findings show that sorafenib interacts synergistically with bortezomib to induce apoptosis in a broad spectrum of neoplastic cell lines and show an important role for the Akt and JNK pathways in mediating synergism.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Bortezomib. Cell Line, Tumor. Drug Synergism. Humans. Jurkat Cells. K562 Cells. MAP Kinase Signaling System / drug effects. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proteasome Endopeptidase Complex / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985072.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Boronic Acids; 0 / Phenylurea Compounds; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 69G8BD63PP / Bortezomib; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


81. le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J: In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell; 2008 Jul 8;14(1):47-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.
  • We examined the leukemic stem cell potential of blasts at different stages of maturation in childhood acute lymphoblastic leukemia (ALL).
  • Cells sorted using the B precursor differentiation markers CD19, CD20, and CD34 were isolated from patient samples and engrafted mice before serial transplantation into primary or subsequent (up to quaternary) recipients.
  • Sorted blast populations mirrored normal B precursor cells with transcription of a number of stage-appropriate genes.
  • These observations inform a model for leukemia-propagating stem cells in childhood ALL.


82. Wei CW, Cheng JY, Huang CT, Yen MH, Young TH: Using a microfluidic device for 1 microl DNA microarray hybridization in 500 s. Nucleic Acids Res; 2005;33(8):e78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both 20mer and 80mer oligonucleotide probes and singly labeled 20mer and 80mer targets, representative of the T-cell acute lymphocytic leukemia 1 (TAL1) gene, have been used to elucidate the performance of this hybridization approach.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):1625-9 [10636854.001]
  • [Cites] Nucleic Acids Res. 1987 Jan 26;15(2):797-811 [3822815.001]
  • [Cites] Anal Biochem. 2001 Aug 15;295(2):149-57 [11488616.001]
  • [Cites] Anal Chem. 2001 Dec 15;73(24):5777-83 [11791544.001]
  • [Cites] Science. 2002 Jan 25;295(5555):647-51 [11809963.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 15;29(24):5163-8 [11812850.001]
  • [Cites] Anal Biochem. 2002 Sep 1;308(1):5-17 [12234458.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 1;30(21):e116 [12409475.001]
  • [Cites] Anal Chem. 2002 Dec 15;74(24):6413-7 [12510768.001]
  • [Cites] Biophys J. 2003 Jan;84(1):124-35 [12524270.001]
  • [Cites] Genome Biol. 2003;4(1):R5 [12540297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1896-901 [12578971.001]
  • [Cites] Angew Chem Int Ed Engl. 2003 Feb 17;42(7):768-72 [12596195.001]
  • [Cites] Nucleic Acids Res. 2003 Mar 1;31(5):e20 [12595569.001]
  • [Cites] Anal Chem. 2003 Mar 1;75(5):1130-40 [12641233.001]
  • [Cites] Anal Biochem. 2003 Jun 1;317(1):76-84 [12729603.001]
  • [Cites] Anal Biochem. 2003 Jun 15;317(2):186-200 [12758257.001]
  • [Cites] J Biomed Sci. 2003;10(6 Pt 1):636-43 [14576466.001]
  • [Cites] Nucleic Acids Res. 2004;32(1):e9 [14718554.001]
  • [Cites] Biotechniques. 2004 May;36(5):790-6 [15152598.001]
  • [Cites] Anal Chem. 2004 Jul 1;76(13):3694-8 [15228343.001]
  • [Cites] Clin Biochem. 2004 Sep;37(9):741-4 [15329310.001]
  • [Cites] Nucleic Acids Res. 1985 Jul 11;13(13):4811-24 [4022774.001]
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):143-50 [10805532.001]
  • (PMID = 15891111.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Oligonucleotide Probes; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 135471-20-4 / TAL1 protein, human
  • [Other-IDs] NLM/ PMC1110744
  •  go-up   go-down


83. Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, Austen B, Catchpoole D, Maher ER, Latif F: Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics; 2009 May 16;4(4):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia.
  • Recently a mouse model of T/natural killer acute lymphoblastic leukemia was used to assess global promoter methylation across the mouse genome using the restriction landmark genomic scanning technique.
  • In this report we determined the methylation status of the SLIT2 gene in leukemias (CLL and ALL).
  • SLIT2 was methylated in all ten leukemia cell lines analyzed (eight completely and two partially methylated).
  • Methylation results in leukemia cell lines and ALL and CLL primary samples were confirmed by direct sequencing of bisulfite modified DNA.
  • [MeSH-major] DNA Methylation. Intercellular Signaling Peptides and Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Nerve Tissue Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Bone Marrow / metabolism. Cell Line, Tumor. CpG Islands / genetics. Humans

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550140.001).
  • [ISSN] 1559-2308
  • [Journal-full-title] Epigenetics
  • [ISO-abbreviation] Epigenetics
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Nerve Tissue Proteins; 0 / Slit homolog 2 protein
  •  go-up   go-down


84. Feola DJ, Garvy BA: Zidovudine plus sulfamethoxazole-trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. Int Immunopharmacol; 2005 Dec;5(13-14):1881-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sulfamethoxazole-trimethoprim and zidovudine (AZT), drugs used often in combination in patients infected with HIV, were investigated for their effects on B cell development in a mouse model.
  • Immune cell populations in the spleen, lung, and peripheral blood were examined, and toxicity to B lineage subtypes in the bone marrow was investigated by phenotypic analysis via flow cytometry.
  • Pre-pro-B, pro-B, early pre-B, and late pre-B cells were assayed for apoptosis and analyzed for cell cycle profile.
  • Total as well as B cell splenic and bone marrow cellularities were significantly decreased by using the drugs concomitantly, while B cell populations in the lungs and percentage in the peripheral blood were not affected.
  • Combination therapy caused significant increases in apoptosis in B cells and granulocytes in the bone marrow, with the late pre-B cell population being the most depleted.
  • The proliferative expansion and differentiation of early pre-B cells (B220+/CD43+/BP-1+/HSA+) to the late pre-B cell (B220+/CD43-/IgM-) stage was blocked, with early pre-B cells accumulating in the proliferative phases of the cell cycle.
  • [MeSH-major] B-Lymphocyte Subsets / drug effects. Bone Marrow Cells / drug effects. Cell Differentiation / drug effects. Trimethoprim, Sulfamethoxazole Drug Combination / toxicity. Zidovudine / toxicity
  • [MeSH-minor] Animals. Anti-HIV Agents. Antigens, CD43 / analysis. Antigens, CD45 / analysis. Apoptosis / drug effects. Bone Marrow / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Granulocytes / drug effects. Immunophenotyping. Isoantigens / analysis. Mice. Mice, Inbred BALB C. Random Allocation. Spleen / cytology. Spleen / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275623.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL064524
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antigens, CD43; 0 / BP-1 alloantigen; 0 / Isoantigens; 4B9XT59T7S / Zidovudine; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


85. Quincoces Suarez JA, Rando DG, Santos RP, Gonçalves CP, Ferreira E, de Carvalho JE, Kohn L, Maria DA, Faião-Flores F, Michalik D, Marcucci MC, Vogel C: New antitumoral agents I: In vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one and derivatives. Bioorg Med Chem; 2010 Sep 1;18(17):6275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New antitumoral agents I: In vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one and derivatives.
  • This set of synthetic compounds exhibited high antitumoral activities regarding in vitro screening against several human tumor cell lines as lung carcinoma NCI-460, melanoma UACC-62, breast MCF-7, colon HT-29, renal 786-O, ovarian OVCAR-03 and ovarian expressing the resistance phenotype for adriamycin NCI-ADR/RES, prostate PC-3, and leukemia K-562.
  • Compounds were also tested against murine tumor cell line B16F10 melanoma and lymphocytic leukemia L1210 as well as to their effect toward normal macrophages.
  • Specific activity against colon cancer cells HT-29 was observed for all tested compounds and suggests further studies with models of colon cancer.
  • Compounds 1, 2, and 4 showed significant cytotoxic activity with IC(50) values 2.3 microM for all human cancer cell lines.
  • Intraperitoneal acute administration of compound 1 and 2 showed very low toxicity rate.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Mice. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20696583.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,5-bis(4-acetoxy-3-methoxyphenyl)-1,4-pentadien-3-one; 0 / Anisoles; 0 / Antineoplastic Agents; 0 / Ketones
  •  go-up   go-down


86. Cheng XW: 1-Acetyl-5,6-dimethoxy-indoline at 123 K. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 7):o1309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the title compound, C(12)H(15)NO(3), all C, N and O atoms lie in a mirror plane.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21202937.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2961829
  •  go-up   go-down


87. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med; 2005 Feb 17;352(7):666-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
  • BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (BNP) is a strong predictor of mortality among patients with acute coronary syndromes and may be a strong prognostic marker in patients with chronic coronary heart disease as well.
  • We assessed the relationship between N-terminal pro-BNP (NT-pro-BNP) levels and long-term mortality from all causes in a large cohort of patients with stable coronary heart disease.
  • METHODS: NT-pro-BNP was measured in baseline serum samples from 1034 patients referred for angiography because of symptoms or signs of coronary heart disease.
  • The median NT-pro-BNP level was significantly lower among patients who survived than among those who died (120 pg per milliliter [interquartile range, 50 to 318] vs. 386 pg per milliliter [interquartile range, 146 to 897], P<0.001).
  • Patients with NT-pro-BNP levels in the highest quartile were older, had a lower left ventricular ejection fraction (LVEF) and a lower creatinine clearance rate, and were more likely to have a history of myocardial infarction, clinically significant coronary artery disease, and diabetes than patients with NT-pro-BNP levels in the lowest quartile.
  • In a multivariable Cox regression model, the hazard ratio for death from any cause for the patients with NT-pro-BNP levels in the fourth quartile as compared with those in the first quartile was 2.4 (95 percent confidence interval, 1.5 to 4.0; P<0.001); the NT-pro-BNP level added prognostic information beyond that provided by conventional risk factors, including the patient's age; sex; family history with respect to ischemic heart disease; the presence or absence of a history of myocardial infarction, angina, hypertension, diabetes, or chronic heart failure; creatinine clearance rate; body-mass index; smoking status; plasma lipid levels; LVEF; and the presence or absence of clinically significant coronary artery disease on angiography.
  • CONCLUSIONS: NT-pro-BNP is a marker of long-term mortality in patients with stable coronary disease and provides prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction.

  • Genetic Alliance. consumer health - Heart Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 May 12;352(19):2025-6; author reply 2025-6 [15888707.001]
  • (PMID = 15716560.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


88. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr; 2006 Mar;19(3):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Severe coronary artery disease, N- terminal pro-B-type natriuretic peptide level, left atrial size, flow propagation velocity, mitral E/Ea ratio, pulmonary atrial reversal velocity, and pulmonary-mitral atrial wave duration predicted an increased LVFP.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500488.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R, Teixeira A, Arthaud M, Riou B, Boddaert J: Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care; 2006;10(3):R82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis.
  • INTRODUCTION: Our objectives were to determine the causes of acute respiratory failure (ARF) in elderly patients and to assess the accuracy of the initial diagnosis by the emergency physician, and that of the prognosis.
  • The main causes of ARF were cardiogenic pulmonary edema (43%), community-acquired pneumonia (35%), acute exacerbation of chronic respiratory disease (32%), pulmonary embolism (18%), and acute asthma (3%); 47% had more than two diagnoses.
  • A missed diagnosis in the emergency department was noted in 101 (20%) patients.
  • The accuracy of the diagnosis of the emergency physician ranged from 0.76 for cardiogenic pulmonary edema to 0.96 for asthma.
  • In a multivariate analysis, inappropriate initial treatment (odds ratio 2.83, p < 0.002), hypercapnia > 45 mmHg (odds ratio 2.79, p < 0.004), clearance of creatinine < 50 ml minute-1 (odds ratio 2.37, p < 0.013), elevated NT-pro-B-type natriuretic peptide or B-type natriuretic peptide (odds ratio 2.06, p < 0.046), and clinical signs of acute ventilatory failure (odds ratio 1.98, p < 0.047) were predictive of death.
  • [MeSH-major] Emergency Medical Services. Emergency Service, Hospital. Hospital Mortality. Respiratory Insufficiency / diagnosis. Respiratory Insufficiency / etiology
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Female. Humans. Male. Physicians. Prognosis. Prospective Studies. Pulmonary Edema / complications. Pulmonary Edema / diagnosis. Pulmonary Edema / mortality. Pulmonary Edema / therapy

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1982 Apr 17;1(8277):907-8 [6122122.001]
  • [Cites] Am J Epidemiol. 1982 Jan;115(1):92-106 [7055134.001]
  • [Cites] Eur Heart J. 1987 Sep;8(9):1007-14 [3665952.001]
  • [Cites] Arch Intern Med. 1988 Jan;148(1):173-6 [3337592.001]
  • [Cites] Arch Intern Med. 1989 Oct;149(10):2277-82 [2802893.001]
  • [Cites] Am J Med. 1991 Mar;90(3):353-9 [1825901.001]
  • [Cites] Ann Emerg Med. 1992 Jun;21(6):669-74 [1590605.001]
  • [Cites] J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A [8376698.001]
  • [Cites] J Gen Intern Med. 1993 Jul;8(7):383-92 [8410400.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77-121 [7582322.001]
  • [Cites] Arch Intern Med. 1997 Jul 14;157(13):1453-9 [9224224.001]
  • [Cites] J Am Geriatr Soc. 2005 Apr;53(4):643-8 [15817011.001]
  • [Cites] Anesthesiology. 2005 May;102(5):885-91 [15851872.001]
  • [Cites] J Intern Med. 2005 Jul;258(1):77-85 [15953135.001]
  • [Cites] J Gen Intern Med. 1986 Nov-Dec;1(6):386-93 [3794838.001]
  • [Cites] Ann Emerg Med. 1999 Nov;34(5):595-603 [10533006.001]
  • [Cites] J Am Coll Cardiol. 2000 May;35(6):1628-37 [10807470.001]
  • [Cites] Eur Heart J. 2000 Aug;21(16):1301-36 [10952823.001]
  • [Cites] Br J Gen Pract. 2000 Jul;50(456):559-63 [10954938.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):1066-78 [11049791.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Feb;56(2):M88-96 [11213282.001]
  • [Cites] J Am Coll Cardiol. 2001 Dec;38(7):2101-13 [11738322.001]
  • [Cites] Eur J Heart Fail. 2002 Jan;4(1):91-8 [11812669.001]
  • [Cites] Circulation. 2002 Jul 23;106(4):416-22 [12135939.001]
  • [Cites] Eur Heart J. 2003 Mar;24(5):442-63 [12633546.001]
  • [Cites] Eur Heart J. 2003 Mar;24(5):464-74 [12633547.001]
  • [Cites] N Engl J Med. 2004 Feb 12;350(7):647-54 [14960741.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Intensive Care Med. 2004 Apr;30(4):647-54 [14985964.001]
  • [Cites] Intensive Care Med. 2004 May;30(5):882-8 [14991092.001]
  • [Cites] Gerontologist. 1970 Spring;10(1):20-30 [5420677.001]
  • [Cites] Acta Med Scand. 1980;207(3):225-30 [7368988.001]
  • [Cites] Postgrad Med J. 1981 Jul;57(669):419-24 [7312736.001]
  • [CommentIn] Crit Care. 2006;10(4):151 [16887005.001]
  • (PMID = 16723034.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550946
  •  go-up   go-down


90. Moon H, Huh J, Cho MS, Chi H, Chung WS: A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology. Korean J Lab Med; 2007 Aug;27(4):253-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology.
  • The differential diagnosis of acute lymphoblastic leukemia (ALL) from other small round blue cell tumors in children is very important for proper treatment, but sometimes difficult.
  • CD45 is expressed on almost all-human leukocytes and not expressed on other small round blue cell tumors.
  • Moreover, CD19 is expressed on all stages of B lineage cells and loss of this antigen is very rare in precursor B-cell ALL.
  • The cytogenetic study showed normal karyotype but amplification of MLL (myeloid/lymphoid or mixed lineage leukemia) gene was suggestive in the fluorescent in situ hybridization.
  • The patient received the standard chemotherapy for acute lymphoblastic leukemia and reached complete remission.
  • [MeSH-major] Antigens, CD19 / analysis. Antigens, CD45 / analysis. Bone Marrow / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Child. Female. Humans. In Situ Hybridization

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094585.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


91. Meloni-Ehrig AM, Tirado CA, Chen K, Jahn J, Suchan S, Scheerle J, Crosby MG, Meany H, Seibel N, Leitenberg D, Heritage DW, Mowrey PN: Isolated del(14)(q21) in a case of precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Aug;161(1):82-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated del(14)(q21) in a case of precursor B-cell acute lymphoblastic leukemia.
  • We present a case of del(14)(q21) as a sole abnormality in a 4-year-old boy diagnosed with precursor B-cell acute lymphoblastic leukemia (pre-B ALL).
  • To our knowledge, this is the first case of isolated del(14)(q21) in pre-B ALL.
  • Both samples showed a del(14)(q21) as the only abnormality.
  • [MeSH-major] Chromosomes, Human, Pair 4 / genetics. Gene Deletion. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080963.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Immunoglobulin Heavy Chains; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


92. Hagler KT, Zori RT, Yuan CM, Gray BA, Moreb JS: Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells. Clin Adv Hematol Oncol; 2005 Jan;3(1):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells.
  • [MeSH-major] Antigens, CD19 / analysis. Burkitt Lymphoma / diagnosis. Hypereosinophilic Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Flow Cytometry. Humans. Immunomagnetic Separation. In Situ Hybridization, Fluorescence. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Adv Hematol Oncol. 2005 Jan;3(1):64-9 [16166970.001]
  • (PMID = 16166969.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19
  •  go-up   go-down


93. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M, Société Française de Greffe de Moëlle et de Thérapie Cellulaire: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol; 2008 May 10;26(14):2264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
  • PURPOSE: Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults.
  • ATCLs show a worse prognosis than B-cell lymphomas.
  • PATIENTS AND METHODS: On behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire, we conducted a retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).
  • RESULTS: The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n = 27), angioimmunoblastic T-cell lymphoma (AITL; n = 11), hepatosplenic gamma/delta lymphoma (HSL; n = 3), T-cell granular lymphocytic leukemia (T-GLL; n = 1), nasal natural killer (NK)/T-cell lymphoma (nasal-NK/L; n = 3) or non-nasal NK/T-cell lymphoma (non-nasal-NK/L; n = 2), enteropathy-type T-cell (n = 1), and human T-lymphotropic virus (HTLV)-1 lymphoma (n = 2).
  • In multivariate analysis, chemoresistant disease (stable, refractory, or progressing disease) at the time of alloSCT and the occurrence of severe grade 3 to 4 acute graft-versus-host disease (aGVHD) were the strongest adverse prognostic factors for OS (P = .03 and .03, respectively).
  • [MeSH-major] Graft vs Tumor Effect / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Stem Cell Transplantation


94. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJ, Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Küppers R, Montesinos-Rongen M, Nagel I, Pott C, Richter J, Román-Gómez J, Seifert M, Stein H, Suela J, Trümper L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R: A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One; 2009 Sep 11;4(9):e6986
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system.
  • In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation.
  • We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias.
  • Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression.
  • As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes--DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1--that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1832-6 [14512355.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):274-80 [12527896.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):3-11 [17489980.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2003;68:69-78 [15338605.001]
  • [Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):808-14 [17299390.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):39-45 [17970783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4844-9 [18353987.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cytokine. 2009 Jan;45(1):8-11 [19071030.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):250-9 [18565646.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):697-704 [18288404.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Pharmacogenet Genomics. 2009 Feb;19(2):95-102 [18987561.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):1-13 [16426940.001]
  • [Cites] Ann Hematol. 2005 Apr;84(4):236-44 [15538567.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):285-90 [16126303.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2795-804 [19168792.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):137-44 [16846474.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Curr Opin Oncol. 2008 Nov;20(6):705-10 [18841054.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6118-28 [16778185.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):137-52 [15064862.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Eur J Immunol. 2004 Jul;34(7):1870-81 [15214035.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Leukemia. 2001 Apr;15(4):583-9 [11368360.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):758-64 [19155300.001]
  • [Cites] PLoS One. 2008;3(3):e1882 [18365023.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):237-42 [18176563.001]
  • [Cites] J Clin Gastroenterol. 2009 Feb;43(2):152-6 [18779738.001]
  • [Cites] Bioinformation. 2007 Apr 10;1(10):420-2 [17597932.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8123-30 [16912190.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2153-63 [17713554.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):1037-43 [18798072.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] J Immunol. 2001 May 15;166(10):5925-34 [11342607.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1824-31 [14512354.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1315-25 [18832655.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):124-31 [12496962.001]
  • [Cites] Mod Pathol. 2008 May;21(5):632-8 [18264085.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2031-2 [19021042.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):821-32 [18273643.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1855-62 [16900213.001]
  • [Cites] Leukemia. 2008 May;22(5):1035-43 [18288132.001]
  • [Cites] Oncogene. 2005 Oct 13;24(45):6848-54 [16007172.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):997-1007 [15746151.001]
  • (PMID = 19750229.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2737286
  •  go-up   go-down


95. Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, Greally JM, Melnick A: An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One; 2008 Mar 26;3(3):e1882
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular heterogeneity of acute leukemias and other tumors constitutes a major obstacle towards understanding disease pathogenesis and developing new targeted-therapies.
  • We predicted that integration of different genome-wide epigenetic regulatory marks along with gene expression levels would provide greater power in capturing biological differences between leukemia subtypes.
  • Gene expression, cytosine methylation and histone H3 lysine 9 (H3K9) acetylation were measured using high-density oligonucleotide microarrays in primary human acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) specimens.
  • We found that DNA methylation and H3K9 acetylation distinguished these leukemias of distinct cell lineage, as expected, but that an integrative analysis combining the information from each platform revealed hundreds of additional differentially expressed genes that were missed by gene expression arrays alone.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2789-90 [15797915.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] BMC Bioinformatics. 2005;6:166 [15992406.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3541-9 [16585178.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6118-28 [16778185.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):194-201 [17210699.001]
  • [Cites] Nucleic Acids Res. 2007;35(3):801-11 [17202157.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):13286-93 [11825903.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8695-700 [12060701.001]
  • [Cites] Genome Res. 2002 Jul;12(7):1112-20 [12097349.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):347-57 [12191634.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2164-71 [12727835.001]
  • [Cites] Leukemia. 2003 May;17(5):910-8 [12750705.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Methods Enzymol. 2004;376:315-34 [14975315.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Cell. 2004 Jun 11;117(6):721-33 [15186774.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2617-25 [17363581.001]
  • [Cites] BMC Genomics. 2007;8:131 [17524140.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10781-6 [11535808.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cell. 2005 Jan 28;120(2):169-81 [15680324.001]
  • (PMID = 18365023.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104348; United States / NICHD NIH HHS / HD / R01 HD044078; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NIGMS NIH HHS / GM / GM007288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones
  • [Other-IDs] NLM/ PMC2266992
  •  go-up   go-down


96. Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, Davis RS: Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol; 2006 Nov 15;177(10):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two members of the recently identified FcR homolog (FcRH) family in mice demonstrate preferential B cell expression.
  • One of these, FcRH3, encodes a type I transmembrane protein with five extracellular Ig domains and a cytoplasmic tail with a consensus ITIM and a noncanonical ITAM.
  • A panel of FcRH3-specific mAbs was generated to define its expression pattern and functional potential on B lineage cells.
  • Although poorly detected on the majority of bone marrow or peripheral blood cells, FcRH3 was readily identified on splenic marginal zone (MZ) and MZ precursor B cells, but not on the bulk of newly formed B cells, follicular B cells, germinal center B cells, and plasma cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082595.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI014782; United States / NIAID NIH HHS / AI / AI14782; United States / NCI NIH HHS / CA / CA13148; United States / NIAID NIH HHS / AI / K08 AI55638
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / FcRH3 protein, mouse; 0 / Immunoglobulin Allotypes; 0 / Immunologic Factors; 0 / Receptors, Fc
  •  go-up   go-down


97. Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, Sahakian E, Kagoda M, Huang G, Hao QL, Sevilla Y, Barsky LW, Zielinska E, Price MA, Wall NR, Dovat S, Payne KJ: IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol; 2009 Apr 1;182(7):4255-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-7 is critical for B cell production in adult mice; however, its role in human B lymphopoiesis is controversial.
  • Here, we examine the role of IL-7 in human B cell development using a novel, human-only model based on coculturing human HSCs on primary human BM stroma.
  • In this model, IL-7 increases human B cell production by >60-fold from both CB and adult BM HSCs.
  • IL-7-induced increases are dose-dependent and specific to CD19(+) cells.
  • STAT5 phosphorylation and expression of the Ki-67 proliferation Ag indicate that IL-7 acts directly on CD19(+) cells to increase proliferation at the CD34(+) and CD34(-) pro-B cell stages.
  • Without IL-7, HSCs in CB, but not BM, give rise to a small but consistent population of CD19(lo) B lineage cells that express EBF (early B cell factor) and PAX-5 and respond to subsequent IL-7 stimulation.
  • As compared with CB, adult BM shows a reduction of in vitro generative capacity that is progressively more profound in developmentally sequential populations, resulting in an approximately 50-fold reduction in IL-7-dependent B lineage generative capacity.
  • These data provide evidence that IL-7 is essential for human B cell production from adult BM and that IL-7-induced expansion of the pro-B compartment is increasingly critical for human B cell production during the progression of ontogeny.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 1;94(11):3781-90 [10572092.001]
  • [Cites] Blood. 1997 May 15;89(10):3554-64 [9160660.001]
  • [Cites] Blood. 2000 Jul 1;96(1):9-23 [10891425.001]
  • [Cites] Immunol Rev. 2000 Jun;175:175-86 [10933602.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2382-9 [10946261.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2803-7 [11023514.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3683-90 [11389003.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] Leukemia. 2002 Mar;16(3):352-61 [11896538.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3091-8 [12626565.001]
  • [Cites] Int J Hematol. 2003 May;77(4):399-407 [12774932.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):773-9 [12872121.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1495-506 [14610045.001]
  • [Cites] J Immunol. 1987 Feb 15;138(4):1082-7 [3492541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):302-6 [2643102.001]
  • [Cites] J Immunol. 1989 Jun 1;142(11):3875-83 [2785567.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2229-38 [1718491.001]
  • [Cites] J Immunol. 1991 Nov 15;147(10):3324-30 [1719075.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1170-8 [7680240.001]
  • [Cites] Cell. 1993 Apr 9;73(1):147-57 [8462096.001]
  • [Cites] J Exp Med. 1993 Jul 1;178(1):113-20 [7686210.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):138-48 [7686930.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2396-405 [7691259.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5382-6 [8202495.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):58-67 [7527823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):377-81 [7831294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1570-4 [7533295.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1519-26 [7699333.001]
  • [Cites] Immunity. 1995 Apr;2(4):331-9 [7719938.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):855-64 [9541580.001]
  • [Cites] Protein Eng. 1998 Jan;11(1):31-40 [9579657.001]
  • [Cites] Leukemia. 1998 May;12(5):764-71 [9593276.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4145-51 [9596660.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):394-7 [9843216.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4509-20 [9845515.001]
  • [Cites] Blood. 1999 Jan 1;93(1):96-106 [9864151.001]
  • [Cites] Exp Hematol. 1999 Aug;27(8):1271-81 [10428504.001]
  • [Cites] Immunity. 1999 Jul;11(1):21-31 [10435576.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):971-9 [15767371.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1197-203 [15837809.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):203-9 [15867576.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):852-60 [15917481.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7325-31 [16301638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1000-5 [16418296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2262-7 [16461915.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):56-66 [16337808.001]
  • [Cites] Exp Hematol. 2006 Sep;34(9):1133-42 [16939806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17852-7 [17090683.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2086-8 [17053062.001]
  • [Cites] Adv Exp Med Biol. 2007;596:57-62 [17338175.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):1068-79 [17617599.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1398-407 [17656007.001]
  • [Cites] BMC Biol. 2007;5:36 [17854505.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):383-92 [18566404.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2297-304 [18566323.001]
  • [Cites] Nature. 1995 Sep 7;377(6544):65-8 [7659163.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 29;764:9-18 [7486595.001]
  • [Cites] Blood. 1996 May 1;87(9):3563-70 [8611678.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1881-90 [8634436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10348-53 [8816803.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):66-72 [8989909.001]
  • [Cites] Blood. 1997 Feb 1;89(3):929-40 [9028324.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1167-76 [10642804.001]
  • (PMID = 19299724.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD001632; United States / NIDDK NIH HHS / DK / 5K01 DK066163; United States / NIDDK NIH HHS / DK / DK066163-06; United States / NIMHD NIH HHS / MD / P20 MD006988; United States / NIDDK NIH HHS / DK / DK066163-02; United States / NIDDK NIH HHS / DK / K01 DK066163-05; United States / NCI NIH HHS / CA / K22 CA111392; United States / NIDDK NIH HHS / DK / DK066163-04; United States / NIDDK NIH HHS / DK / K01 DK066163-01; United States / NIDDK NIH HHS / DK / K01 DK066163-06; United States / NIDDK NIH HHS / DK / DK066163-03; United States / NIMHD NIH HHS / MD / P20 MD001632-02; United States / NIGMS NIH HHS / GM / R25 GM060507; United States / NIGMS NIH HHS / GM / R25 GM060507-02; United States / NIDDK NIH HHS / DK / K01 DK066163-02; United States / NIDDK NIH HHS / DK / K01 DK066163-04; United States / NIDDK NIH HHS / DK / DK066163-01; United States / NIDDK NIH HHS / DK / K01 DK066163; United States / NIDDK NIH HHS / DK / K01 DK066163-03; United States / NIDDK NIH HHS / DK / DK066163-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-7
  • [Other-IDs] NLM/ NIHMS95094; NLM/ PMC2659466
  •  go-up   go-down


98. Kempf T, Wollert KC: Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz; 2009 Dec;34(8):594-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated circulating levels of GDF-15 identify high-risk individuals across the cardiovascular continuum, from stable coronary artery disease to acute coronary syndrome and heart failure.
  • The association of GDF-15 with outcome in these conditions is independent of clinical risk factors and established biomarkers, including NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin.
  • The prognostic information provided by GDF-15 in cardiovascular disease may inform patient management, e.g., by identifying patients with non-ST segment elevation acute coronary syndrome who benefit from an invasive strategy, or by monitoring treatment response in heart failure.
  • [MeSH-major] Cardiovascular Diseases / blood. Cardiovascular Diseases / diagnosis. Growth Differentiation Factor 15 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):253-62 [18164124.001]
  • [Cites] J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60 [17825714.001]
  • [Cites] Circulation. 2007 Oct 2;116(14):1540-8 [17848615.001]
  • [Cites] Eur J Heart Fail. 2008 Sep;10(9):824-39 [18760965.001]
  • [Cites] Circ Res. 2006 Feb 17;98(3):351-60 [16397141.001]
  • [Cites] Herz. 2008 Mar;33(2):115-21 [18344030.001]
  • [Cites] Eur Heart J. 2008 Oct;29(19):2327-35 [18664460.001]
  • [Cites] Endocrinology. 2009 Apr;150(4):1688-96 [19074584.001]
  • [Cites] Cardiovasc Res. 2008 Jul 15;79(2):294-303 [18359786.001]
  • [Cites] Eur Heart J. 2007 Dec;28(23):2858-65 [17977844.001]
  • [Cites] Circ Cardiovasc Genet. 2009 Jun;2(3):286-92 [20031597.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):226-32 [10413734.001]
  • [Cites] Herz. 2009 Mar;34(2):141-7 [19370331.001]
  • [Cites] Eur Heart J. 2009 Nov;30(22):2749-57 [19666898.001]
  • [Cites] Cell Tissue Res. 2004 Nov;318(2):325-33 [15459768.001]
  • [Cites] Arthritis Rheum. 2007 Mar;56(3):753-64 [17328047.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):2007-18 [12748317.001]
  • [Cites] Circulation. 2007 Feb 27;115(8):949-52 [17325253.001]
  • [Cites] Hypertension. 2008 Feb;51(2):309-18 [18158353.001]
  • [Cites] Circ Res. 2007 Jan 5;100(1):61-9 [17138942.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4610-9 [15958647.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 1;178(5):534-41 [18565955.001]
  • [Cites] Clin Chem. 2007 Feb;53(2):284-91 [17185363.001]
  • [Cites] Am J Respir Crit Care Med. 2008 May 1;177(9):1018-25 [18263797.001]
  • [Cites] Eur Heart J. 2009 Oct;30(19):2346-53 [19561023.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2148-59 [18480207.001]
  • [Cites] Circ Res. 2006 Feb 17;98(3):342-50 [16397142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9 [9326641.001]
  • [Cites] Circulation. 2007 Nov 27;116(22):2634-53 [17951284.001]
  • [Cites] Circulation. 2007 Feb 27;115(8):962-71 [17283261.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):4983-6 [16707416.001]
  • (PMID = 20024638.001).
  • [ISSN] 1615-6692
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Growth Differentiation Factor 15
  •  go-up   go-down


99. Fistonić I, Canić T, Duić Z, Fistonić M, Ciglar S: [Alternative hormone therapy in postmenopause]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the fact that hormonal combination used in huge Wpmen's Health Initiative (WHI) is not common all over the world, and treated population is, because of age, in risk per se, study results have consternated not only lay users, but prescribers too.
  • This review shows not only mandatory list of possibilities, but also emphasises which of the alternative and complementary treatments are evidence based regarding published randomized controlled trials.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lijec Vjesn. 2006 Jul-Aug;128(7-8):252; author reply 252-3 [17087144.001]
  • (PMID = 16808100.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 80
  •  go-up   go-down


100. Matsusaka S, Tohyama Y, He J, Shi Y, Hazama R, Kadono T, Kurihara R, Tohyama K, Yamamura H: Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochem Biophys Res Commun; 2005 Mar 25;328(4):1163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell polarization and migration in response to CXCL12 is essential for hematopoiesis.
  • To investigate the role of Syk in CXCL12/CXCR4-induced signaling, wild-type Syk or its dominant-negative form (DN-Syk) was introduced in mouse pro-B cells, BAF3.
  • Overexpression of wild-type Syk caused enhanced polarization, whereas DN-Syk inhibited cell polarity due to the loss of contractile structure at the rear end, and the altered phenotype was enhanced after CXCL12 stimulation.
  • As beta1 integrin-mediated cell adhesion was inhibited, decreased adhesion might promote motility.
  • These results demonstrate that Syk participates in CXCL12-induced cell polarization, which occurs in concert with cell adhesion mediated by beta1 integrin.
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Movement / drug effects. Cell Movement / physiology. Cell Polarity / drug effects. Cell Polarity / physiology. Cells, Cultured. Chemokine CXCL12. Dose-Response Relationship, Drug. Intracellular Signaling Peptides and Proteins. Mice. Recombinant Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707999.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Enzyme Precursors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Recombinant Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase
  •  go-up   go-down






Advertisement